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Abstract
Prostate Cancer (PCa) is the most common non-cutaneous cancer in North
American men. Multi-parametric magnatic resonance imaging (mpMRI) has the
potential to be used as a non-invasive procedure to predict locations and prognosis
of PCa. This study aims to examine non-cancerous pathology lesions and normal
histology that could mimic cancer in mpMRI signals. This study includes 19
radical prostatectomy specimens from the London Health Science Centre (LHSC)
that were marked with 10 strand-shaped fiducials per specimen which were used
as landmarks in histology processing and ex vivo MRI. Initial registration
between fiducials on histology and MR images was performed followed by the
development of an interactive digital technique for deformable registration of in
vivo to ex vivo MRI with digital histopathology images. The relationship between
MRI signals and non-cancerous abnormalities that could mimic PCa has not been
tested previously in correlation with digital histopathology imaging. The
unregistered mp-MRI images are contoured by 4 individual radiology observers
according to the Prostate Imaging Reporting and Data System (PI-RADS).
Analysis of the radiology data showed prostatic intraepithelial neoplasia (PIN),
atrophy and benign prostatic hyperplasia (BPH) as main non-cancerous
abnormalities responsible for cancer like signals on mpMRI. This study will help
increase the accuracy of detecting PCa and play a role in the diagnosis and
classification of confounders that mimic cancer in MR images.

Keywords
Prostate imaging, Prostate non-cancerous abnormalities, Prostate image
regestirations, in-vivo prostate MRI, Prostate cancer.
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Chapter 1

1
1.1

Introduction
Prostate Cancer Epidemiology

Prostate cancer (PCa) is one of the most common cancers in North American men
and the developed world. It is the second leading cause of cancer in men after skin
cancer. According to the World Health Organization (WHO) (Globocan 2012),
approximately that 1.1 million men worldwide were diagnosed with PCa with an
estimated seventy-percent of cases established in developed countries (Figure
1.1). These countries include USA, Canada, Australia, and New Zealand as well
as Northern and Western European regions, which demonstrates the wide-ranging
geographic variation of incidence with a twenty-five fold increase in incidence
compared to developing countries [1].
Several influences are responsible for incidence variations, including methods of
data gathering and analysis, socio-economic status (SES) as well as access to the
healthcare system. To further demonstrate this variation, the introduction of PCa
screening tests with Prostate Specific Antigen (PSA) in the late 1980s and early
1990s has significantly increased asymptomatic PCa cases detected in North
America and the United Kingdom [2].
In 2012, it was estimated that 307,000 deaths were due to PCa, with a tenfold
increase in the new incidence rate compare to the mortality rate [1]. Despite the
increase in incidence rates of PCa in almost all countries, the mortality rate is
higher in developing countries compared to a significant decline in developed
countries [3] (Figure 1.2). The developed healthcare system is associated with a
high level of PCa diagnosis accompanied by low mortality rate. The Canadian
Cancer Society and The National Cancer Institute Surveillance, Epidemiology and
End Results (SEER) in the USA estimated that new cases of diagnosed PCa for
2015 were 24,000 in Canada and 220,800 in the USA. The mortality numbers
were 4,100 in Canada and 27,540 in the USA. In Canada, PCa represents 24% of
all cancer cases affecting men, compared to 13.3% in the USA.
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Similarly, Canadian records reveal that PCa is responsible for 10% of all
estimated cancer deaths compared to 4.7% in the USA with a five-year survival
rate of 96% and 98.9% in Canada and the USA respectively [4, 5].
With many risk factors associated with PCa, five leading causes have been
discovered to have the strongest significance on PCa. These include
race/ethnicity, age, family history, diet, and genetics, which will be discussed
below [6].

1.1.1

Race/Ethnicity

Several studies have concluded that black men or those with African descent have
a higher risk of PCa compared to Caucasian men as well as a higher mortality rate
with a 2.5-fold increase between the two racial groups [5]. Also, studies have
shown that black men have a greater risk of being diagnosed with an advanced
PCa grade at a younger age compared to Caucasian men in the same age groups.
The lowest incidence of PCa was reported in Asian races and communities [1, 79]. Data from the Detroit (SEER) registry confirms with the radical prostatectomy
specimen analysis, that the cancer volume and Gleason score were higher in
Black men. They have an increased risk for more advanced and distant metastasis
with a ratio of 4:1 compared to Caucasian men. These findings support the faster
growth and transformation to clinically significant disease in Black men in
comparison to Caucasian men [10].
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(Figure 1.1) World map presenting the distribution of PCa incidence
worldwide per 100,000 (Globocan 2012) [1]

(Figure 1.2) International incidence and mortality of PCa worldwide per
100,000. (Adopted from Globocan 2012) [1]. The graph presents a high incidence
of PCa associated with low mortality in developed countries while developing
countries sustained similar mortality rates despite low incidence rates.
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1.1.2

Age

Before the introduction of PSA screening, PCa was called the disease of old age.
The risk of diagnosis of PCa in men under the age of forty is very low. It is
estimated that 1 in 55 men will be diagnosed with PCa in the age group of 40-60
years. However, this ratio will increase to 1 in 7 men in the age group of 60-80
years [11]. Autopsy results in prostate tissue sampling illustrate that 75% of men
over 80 years old will develop latent microscopic PCa at some point in their lives
[12, 13]. Other studies have indicated that 26% of men over the age of 75 will be
diagnosed with high-risk disease and clinically significant cancer. Clinically
significant cancer is defined as cancer with a volume of more than 0.5 cm3 and/or
a Gleason score of more than 6 [14]. Advanced age at the diagnosis of PCa is one
of the major risk factors for increased Prostate Cancer-Specific Mortality (PCSM)
[15].

1.1.3

Family and Socioeconomic Status

The family history of PCa is another well-known risk factor that presents a
sufficient warrant for early screening and close monitoring to detect early PCa
when it arises. Studies demonstrated that the risk of PCa is higher with brothers
involvement than father involvement [16]. The family history of PCa is a greater
risk factor for a more fatal and aggressive disease than for the isolated incidence
of PCa, which points to the association of fatal PCa to a genetic subgroup [17].
However, PCa risk factors are more complicated than initially thought. It has been
reported that higher Socioeconomic Status (SES) groups demonstrate high
incidents of PCa with a low mortality rate across all racial and ethnic groups [18].
Research studies report the early detection of PCa is possible due to the increase
of frequent screening and an advanced health care system. Studies have also
indicated that regular screening is responsible for a small percentage of discovery.
Additional factors should be considered and examined carefully for further
understanding of the Socioeconomic Status and its relation to a higher PCa
incidence [19].
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1.1.4

Diet

The fourth factor is the type of diet patients follow and its relationship to PCa
incidence. Diets that contain a high fiber content such as vegetables and low fat
have been associated with a decreased incidence of PCa. However, diets that
involve high caloric content fatty foods such as red meat, dairy products and
calcium from dairy products were also associated with increased incidence of PCa
[20]. Some authors report that the consumption of fish three times or more per
week was associated with a decreased risk of PCa as well as lowering the chance
of metastatic disease development [21]. The exact correlation between types of
food and PCa is still unknown with unclear pathway. Further examinations should
address these correlations in more detail.
Selenium was initially considered to lower the incidence of PCa. Results from
other studies presented a moderate decrease in PCa risk with high serum selenium
intake [22]. However, additional studies failed to replicate these findings and
suggested no association between PCa and selenium serum level [23]. In recent
cohort studies involving selenium and Vitamin E in a chemopreventive nutrient
trial, no associations were discovered between serum selenium level and PCa [24,
25].

1.1.5

Obesity

Obesity is one of the public health challenges that society faces, as it has
increased rapidly among the general population. Obesity is related to various
diseases and types of cancer (e.g. breast and colon cancer). Obesity was not
considered as a risk factor for PCa until recently. Obese men would have a higher
risk of aggressive diseases with a lower chance of nonaggressive diseases if they
were affected with PCa [26, 27]. This finding is potentially biased due to the
difficulty of diagnosing PCa in obese men. To briefly explain, obese men have a
larger volume of blood compared to non-obese men, this, in turn, will influence
the PSA serum level to the lower range. Larger prostate sizes in obese men have a
higher chance of missing the tumour during biopsies. Obesity has also been
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found to have an adverse impact on the sensitivity of digital rectal exams (DRE)
[28, 29].
Obesity does not only affect the diagnosis of PCa, but it has an impact on
treatment options and outcomes. After a prostatectomy and external radiation
therapy, obesity was linked to biochemical failure. Furthermore, obesity is
associated with a greater rate of complications and poor side effects after
androgen-deprivation therapy as well as higher rate of PCSM [30, 31]. Obesity
has been linked to increasing serum Insulin-like Growth Hormone (IGF-1), which
has a strong linkage to increasing PCa risk [32].

1.2
1.2.1

Anatomy and Histology of Prostate Gland
Prostate Gland Anatomy

The prostate gland is one of three accessory glands of the male genital
reproductive system besides seminal vesicles and bulbourethral (Cowper’s) gland.
It is a funnel-shaped organ, located in the true anatomical pelvic boundary. The
prostate base is immediately below the bladder neck, and the apex is just above
the urogenital diaphragm. The proximal half of prostatic urethra runs steeply
downwards and forward through the center of the gland, then at the level of
verumontanum (mid prostatic urethra) it twists anteriorly [33]. The anterior
prostate surface is slightly concave and is located behind the pubic bone and
connected to it with the puboprostatic ligament. The posterior surface is
horizontal with a midline depression in contact with rectal ampulla. The prostate
is separated from the rectum by a dual film thin like fascia termed “Denonvillier’s
Fascia.” Extraperitoneal fat surrounds the prostate in the space of Retzius
anteriorly, where the prostatic dorsal venous plexus is found. The venous plexus
is responsible for the blood supply and drainage of the penis. The levator-ani
muscles surround the lateral surface of the gland bilaterally. The prostate is
pierced by ejaculatory ducts on the posterior surface laterally and run obliquely
and forward towards the posterior surface of the urethra at the level of
verumontanum where they join the prostatic urethra [34].
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The essential and central landmark of the prostate gland is the urethra, which has
an average length of 3-4 cm and a mid-urethral 35° angulation anteriorly. The
urethral curvature divides the urethra into two sides: proximal and distal with an
almost identical length. The verumontanum structure arises from the posterior
wall of the urethra where this bend occurs. It continues and points distally to form
the crista urethralis [35] (Figure 1.3). The majority of prostatic acini and
ejaculatory ducts open in the verumontanum. The periurethral glands of Littre,
which have a smaller opening are found along the whole length of the urethra. A
circumferential muscle sheath layer covers the entire urethra and is attached
between the two urethral sphincters. Proximally, the circumferential sheath
contains smooth muscle with the role of preventing retrograde ejaculations.
Distally, the apex region consists of smooth and striated muscle, which has a
primary role in micturition control [36].
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(Figure 1.3) The urethra structures at the level of verumontanum. Low
magnification of a prostate tissue section with hematoxylin and eosin stain
showing urethral structure at the level of verumontanum and crista urethralis, an
opening site for prostatic glands and ejaculatory duct.
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1.2.2

Embryology of the Prostate Gland

The prostate gland and the adjacent structure develops from 2 different origins.
The prostate gland arises from urogenital sinus that develops from epithelial buds,
while the Seminal Vesicles (SV), Epididymis, Vas Deferens (VD) and Ejaculatory
Ducts (ED) develop from the Mesonephric Duct (Wolffian duct). The
mesenchyme stimulates the urogenital sinus epithelium proliferation, ductal
morphogenesis, and differentiation. Through the feedback loop mechanism, the
epithelial tissue signals the mesenchyme tissue (undifferentiated connective
tissue) to proliferate and differentiate into smooth muscle cells around the
epithelial ducts. This development is under the regulation of androgen produced
from the testis, which is considered the growth factor promoter to the prostate
gland [37, 38].
The mesenchymal tissues continue growing to evolve the dome-shaped base of
the prostate. During the mesenchymal growth, the ejaculatory duct formation
continues to grow and proliferate towards the future verumontanum structure at
urethral midway. The area around the ejaculatory duct continues to proliferate and
form the central zone of the prostate. By the 10th week of embryonic life, the
epithelial buds begin to branch mainly from the posterior and lateral regions of
the urethral wall. The prostate duct formations and solid epithelial tissue continue
to grow after birth at a very slow rate with a constant prostate size (less than 2 cm
in diameter) until puberty [35, 38]. By the age of 20, and under the effect of
androgen on the prostate, the gland reaches approximately 20 g in weight and
remains within this range until the age of 30.

1.2.3

Microscopic Anatomy of the Prostate Gland

According to Dr. McNeal’s model, the prostate gland is composed of glandular
and non-glandular regions or districts that cannot be separated by gross anatomy.
The glandular component contains Peripheral, Central and Transitional Zones that
are only identified on a microscopic level. The non-glandular tissues are anterior
fibromuscular stroma and prostatic capsule. Additionally, McNeal includes the
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periprostatic and striated sphincters, nerve and blood supply within the nonglandular tissue component [39, 40].

1.2.3.1

Peripheral Zone (PZ)

The Peripheral Zone composes 70% of the prostate gland volume. It is the most
common region for (chronic) Prostatitis, Prostatic Intraepithelial Neoplasia (PIN)
and Carcinoma. It occupies the posterior, lateral and distal anterolateral area
(apex) of the gland, which gives it a horseshoe shape. The peripheral zone ducts
open into the urethra as a double row every 2 mm on the posterolateral surface for
about 1.5 cm from the verumontanum proximally to the apex distally [36, 40].
The coronal section of the prostate gland demonstrates that the ducts of the
peripheral zone occupy the lateral area around the distal urethra extensively at a
15° angle. The ducts are distant from the urethra toward the prostate capsule and
have branches arched anteriorly and posteriorly giving origins to groups of acini.
The acini are similar in shape and thickness. Also, the acini are distant from the
urethra. Peripheral zone acini have a simple structure and are oval or rounded in
shape surrounded by loose woven stroma and collagen (Figure 1.4) [33, 39, 40].

1.2.3.2

Central Zone (CZ)

The central zone composes 25% of the gland volume. It is responsible for 1-5% of
the incidence of carcinoma and inflammation. The central zone is a cone-shaped
structure that encloses the Ejaculatory Ducts (ED) with its base distal to the
bladder neck, and its apex pointed at the verumontanum. The base of the prostate
gland is formed mostly by the CZ. The ducts open in the verumontanum just
around the ED orifices and fan out towards the base. The central zone acini
display more complex structure than the peripheral and transitional zones. The
acini are larger in size, particularly towards the capsule with papillary folding and
intraluminal ridges, which resemble a cribriform appearance. This cribriform
glandular structure shape is occasionally misidentified as Prostatic Intraepithelial
Neoplasia (PIN). The central zone has a higher stromal to epithelial ratio
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compared to other prostatic tissues. The stroma consists of compact interlacing
smooth muscle bundles (Figure 1.5) [33, 36, 40].
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(Figure 1.4) Peripheral zone. Simple rounded or oval glands with loose woven
stroma in between. 20X magnification power.

(Figure 1.5) Central zone. Glands structures are more complex (Cribriform) with
compact interlacing stromal appearance. 15X magnification.
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1.2.3.3

Transition Zone (TZ)

Initially, the Transition Zone (TZ) was not described by Dr. McNeal until 1978.
He published a report in 1972 stating that Benign Prostatic Hyperplasia (BPH)
arised from periurethral glands. He concluded that it is a benign nodular
hyperplasia of the prostatic urethra [41]. The new anatomical concept emerged
after the fundamental change in Dr. McNeal’s report in 1978 stating that the
origin of BPH is in the transitional zone [42, 43]. The TZ surrounds the proximal
prostatic urethra, forming about 5% of prostatic volume, however, it can grow
significantly and become more than the remaining prostate tissue combined. The
TZ ducts exit the urethra as a single slit on the posterolateral surface just proximal
to urethral angulation occurrence. The ducts extend laterally and curve sharply
anteriorly and branches in the direction of the bladder neck. There is a clear
boundary between TZ and the residual glandular tissue made by fibromuscular
tissue, which enables its visualizations by transrectal ultrasound. The acinar
component of the TZ is similar to the PZ with a small rounded or oval structure
encircled by more compressed stroma composed of a compact, dense, interlacing
smooth muscle bundle. This smooth muscle blends with pre-prostatic sphincter
stroma and Anterior Fibromuscular Stroma (AFMS) [33, 40].
Rather than BPH, the TZ is responsible for 20% of prostate carcinoma.
Pathologists refer to PZ and CZ as outer prostate or non-transition zone and the
TZ and AFMS as the inner prostate [44]. Transition zone cancer is usually large
in volume with high PSA serum level, although it is accompanied by low Gleason
score [45]. Cancer arising from TZ is associated with high risk of bladder neck
involvement with anterior positive surgical margins and low risk for
neurovascular bundle invasions, Extra Prostatic Extension (EPE) or Seminal
Vesicles (SV) [45, 46].

1.2.3.4

Anterior Fibromuscular Stroma (AFMS)

According to Dr. McNeal’s description, AFMS is an apron of wedge-like shaped
tissue. It runs from the bladder neck over the anteromedial surface of the prostate
proximally and becomes narrow distally to connect with the prostatic urethra at
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the apex [40]. It is attached to the periprostatic sphincter and Transition zone from
its posterior dorsal surface proximally, and the semicircular striated muscle
towards the apex distally. The lateral margin of AFMS interlaces with prostatic
capsule laterally above, providing cover to most of the anterior margin of the PZ.
The AFS structure is similar to the bladder neck with a large compact smooth
muscle bundle. However, these smooth muscle bundles are more randomly
oriented and are divided in between with bands of dense fibrous tissue [33, 36,
40].

1.2.3.5

Prostate Capsule

The capsule of the prostate gland consists of a dual layer, a smooth muscle layer
located internally with the collagen layers externally. The inner smooth muscle
layer grows transversely and inwards to blend with the smooth muscle
surrounding the prostatic glandular acini. Clear identifications between the two
layers is quite difficult even with the assistance of viewing these layers on the
microscopic level [35]. To further explain this difficulty, the multilayer
collagenous fascia surrounds the gland, which varies in thickness across the
different areas of the prostate. This fascia may blend with the capsule depending
on the location. The capsule is ill-differentiated and contains varied tissue
between smooth muscles, striated muscles and fibrous tissue in the region of the
apex. The inconsistency of prostate capsule structure leads to not being
considered as a real anatomical feature [47, 48]. Since the prostate gland is
surrounded by abundant amounts of adipose tissue, pathologists use this as a
landmark for extra-prostatic tissue identification and the assessment of cancer
spreading outside the gland in prostate biopsy or total prostatectomy specimens.

1.2.4

Vascular Supply

The arterial supply to the prostate originates from two sets of arteries on each
side, known as the superior and inferior prostatic pedicles. Commonly, the
superior prostatic pedicle (prostate artery) is a branch of the prostatic-vesicular
artery that supplies the inferior bladder portion and seminal vesicles. The origin
of the prostate artery is variable. For instance, the cadaveric specimens study
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demonstrated that the prostate artery might originate from other roots [49]. The
prostate artery then divides into two branches adjacent to the base of the prostate
gland laterally, the urethral artery (medial branch) and the capsular artery (lateral
branch). The urethral artery is responsible for blood supply to the proximal
prostatic urethra until the crista urethralis, transitional zone, and paraurethral
glands. It penetrates the gland on prostatovesicular junction proceeding in a
perpendicular course in relation to the urethra before having a 90° angle turn to
run parallel to it. The capsular artery has a caudal descending direction towards
the apex and external to the prostatic capsule. Capsular artery has perforated
branches that penetrated the prostatic capsule providing blood supply to the
prostate capsule, central zone, and distal urethra. The capsular artery receives
various anastomosis from the inferior prostatic pedicle branch after forming
plexus around the distal prostate-urethral junctions [34, 50, 51].

1.2.5

Neurovascular Bundles of the Prostate

The prostate neurovascular bundles are formed on a groove between the
posterolateral borders of the prostate anteriorly and rectum posteriorly. It consists
of the cavernous nerves that arise from the pelvic plexus to supply corpora
cavernosa and corpora spongiosum after entering the helium of the penis inferior
to the pubic bone. It has a major role in erectile function. This gives the bundle its
significant surgical landmark due to the direct impact on post-surgical recovery as
well as resuming erectile function and sexual activity. The cavernous nerves are
joined by arterial and venous branches from the prostatovesicular artery and veins
admixed together to form the bundle. The bundles run between the prostatic fascia
medially, and levator ani muscle fascia laterally. The cavernous nerves contain
sympathetic fibres originating from T11 to L2 ganglia as well as parasympathetic
elements originating from ventral rami of S3 and S4 [34, 52].

1.2.6

Normal Histology of the Prostate Gland

The essential physiological function of the prostate gland is to sustain nutrition to
sperms during ejaculation with quick and efficient ejections of small volumes of
fluid. The prostate has a large storage capacity with a low secretory volume. The
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muscular component allows the gland to carry out these functions [35]. The ducts
and acini are both lined with tall columnar secretory epithelium cells with pale to
clear cytoplasm, secretory vacuoles, and dark nuclei. The secretory vacuoles are
tightly packed in PZ and TZ; however, they are wider and less dense in the CZ
[33, 35, 39]. Secretory cells produce Prostate-Specific Antigen (PSA) and
Prostate Specific Acid Phosphatase (PSAP) from all prostate zones. Also, they
produce pepsinogen II, lactoferrin, and plasminogen activator from the CZ. They
stain positive with PSA and PSAP and negative with high molecular weight
cytokeratin stain due to the lack of immunoreactivity [35].
The secretory cells are found on the layer of basal cells, which are isolated from
the basement membrane and stroma. Basal cells are flattened, elongated in shape,
with slender dark nuclei and are progressively scant or with no cytoplasm
comparable to fibroblasts. They are arranged parallel to the basement membrane.
Occasionally, the basal cells are not seen, or they may be presented partially
around the ducts and acini of the prostate gland. Basal cells stain positive for high
molecular weight cytokeratin or P63 stain. They are absent in the existence of
adenocarcinoma.
The distal ducts near the urethra are lined with urothelial cell similar to the
urethral epithelium. The urothelium is a spindle-shaped like cell with scant
cytoplasm. The nucleus sustains a nuclear groove. The long axes of these grooves
are parallel to the basement membrane [35, 39].
The last epithelial cell type is endocrine-paracrine cells that has unknown
physiologic functions. They are found between the basal and secretory cell with
the lateral dendritic process [39]. These cells are not easily identified with routine
Hematoxylin

and

Eosin

staining

(H&E),

that

require

special

immunohistochemical stains of antibodies like chromogranin A, serotonin, and
neuron-specific enolase [53, 54]. Although, the paracrine cell function is still
unknown, they contain serotonin granules and various peptide hormones such as
somatostatin, calcitonin, and bombesin [33, 35, 39, 54].
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1.2.7

Mimickers of Prostate Cancer

Pathologists face a challenging task in diagnosing PCa, especially in a small
glandular amount in well differentiating cancer lesions or other deviations from
normal histology tissue. The mimickers are classified according to their glandular
size in comparison to Gleason scoring. There are small, medium and large
glandular size mimickers. However, the majority of mimickers fall into the small
gland category [55].
The following section discusses three noncancerous pathological lesions. We have
observed that atrophy, Prostatic Intraepithelial Neoplasia (PIN), and Benign
Prostatic Hyperplasia (BPH) were the major confounders of prostate cancer on
MRI (discussed further in section 3). These lesions can result in a false positive
cancerous-like signal in MRI on prostate gland images.

1.2.7.1

Atrophy

Atrophy is one of the most common discoveries in prostate tissue during biopsy
or retrieval of the whole prostate specimen from radical prostatectomy. There are
two main characteristic types of atrophy, diffuse and focal. Androgen deprivation
is responsible for diffuse atrophy whether through orchiectomy, surgically or
chemically through antiandrogen or luteinizing releasing hormone agonists [56].
Focal Atrophy has no known link to androgen deprivation, however, earlier
studies refer to focal atrophy as a part of aging. Other research studies have
indicated that focal atrophy could be a result of either acute or chronic
inflammation [35, 57].
The focal atrophic glands are typically heterogeneous patches, distorted and
relatively small in size. They are accompanied by flattened epithelium and
hyperchromatic nuclei. Some focal atrophic acini are present with the complete
lack of a basal cell layer [56]. There are multiple variants for atrophic gland
subtypes. Nevertheless, these subtypes share the same main histologic features.
No challenges exist in identifying atrophic glands with high power magnifications
except for Post-Atrophic Hyperplasia (PAH). The challenges the pathologists face
in recognizing PAH are owed to the increase of the cytoplasmic basophilic
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appearance and increase in acinar architecture. Other types of atrophic glands are
conceivably mistaken with adenocarcinoma on low power magnifications. Four
distinctive variants of prostate focal atrophy are discussed further.

1.2.7.1.1 Simple Atrophy (SA)
The first typical variant and the most common type of atrophy is known as the
Simple Atrophy (SA). The acini appear basophilic on a low-power magnification
due to the diminished amount of cytoplasm. Although the acini appearance are
irregular and angulated, they still appear within a relative average calibre. The
cells are reduced in the cytoplasm with no change to the nucleus size and shape
with the nucleoli appearing smaller with chronic inflammation. In summary, they
are mimicking adenocarcinoma (Figure 1.6) [35, 56].

1.2.7.1.2 Post-Atrophic Hyperplasia (PAH)
The acini in PAH are small and rounded with a lobular arrangement (Figure 1.7).
They are often accompanied by dilated ducts called feeder ducts, resulting in the
appearance of resting breast lobules. Therefore, some authors and pathologists
termed PAH as lobular atrophy [56]. PAH is basophilic in appearance with low
cuboidal cell shape, scant cytoplasm and a small to a medium-sized nucleus with
mild to moderate enlargements compared to adjacent normal epithelial cells. This
results in the confusion with adenocarcinoma [35, 56, 58]. A tight arrangement of
multiple small acini raises the impression of tissue proliferation when relating to
normal tissue and hyperplasia expression [59].
Although the basal cell layer is present in PAH acini, it is rarely identified with a
light microscope using a hematoxylin and eosin stain. The basal cells are present
and

appear

in a distorted and fragmented

layer with

the use of

immunohistochemically high-molecular-weight cytokeratin stain. The PAH is
associated with stromal involvement. Stromal changes are varied and are capable
in presenting as a smooth muscle atrophy to dense sclerotic changes that have a
significant impact on acini shape and luminal space [58].
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PAH is commonly associated with chronic inflammatory cells in the adjacent
stroma or the luminal space [56]. PAH represents the most extreme form of
morphological changes of atrophic acini, which may be misdiagnosed as an
adenocarcinoma followed by unnecessary treatment intervention.

1.2.7.1.3 Simple Atrophy with a Cystic Formation
The acini in simple atrophy with cystic formation reveal that shape and diameter
vary. They range from a small to large calibre that produce a sieve-like
appearance in the gross sections as well as cystic-like appearances under the
microscope. The acini are arranged tightly with little to no stromal in-between.
The cells have a little cytoplasm. There is no relation observed between simple
atrophy with cystic formation and chronic inflammation [35, 56] (Figure 1.8).

1.2.7.1.4 Partial Atrophy
In contrast with the various types of atrophy, partial atrophy acini have a nonbasophilic appearance on low magnification. The cytoplasm is reduced in the
partial atrophic epithelial cells compared to the normal glandular epithelium. The
majority of cytoplasm commonly presents laterally to the nucleus leading to
enhanced internuclear spaces. This results in a low-to-pale appearance on low
power magnification (Figure 1.9). The partial atrophic glands may become
present in small to medium sizes with intraluminal dark pinkish or crystalloid
secretion that could mimic adenocarcinoma of the prostate. Partial atrophy is
frequently viewed as simple atrophy presenting the proposition to consider that
partial atrophy as a stage of atrophic changes [35, 56].
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(Figure 1.6): Simple Atrophy. Angulated glands with basophilic appearance
with very low to no cytoplasm with normal size, dark nuclei. 20X magnification.

(Figure 1.7) Post-Atrophic Hyperplasia (PAH). Low power image shows a
central dilated duct (feeding duct) surrounded by atrophic acini.
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(Figure 1.8) Simple atrophy with cystic formation. Simple cystic atrophy,
distinctive with medium to large calibre glands, rounded in shape with no or very
little cytoplasm. 10X magnification.

(Figure 1.9) Partial atrophy. Pale cytoplasm is laterally positioned with
increased internuclear distance. Glands are also with pink to eosinophilic
Intraluminal secretion. 15X magnification.
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1.2.7.2

Prostatic Intraepithelial Neoplasia (PIN)

Historically, McNeal and Bostwick described PIN as premalignant lesions and
identified it as a intraductal dysplasia [60]. Previously, PIN was classified into
three categories according to epithelial dysplasia; mild, moderate and severe.
Pathologists currently use a newer classification, which includes only two classes,
low-grade, and High-Grade PIN (HGPIN). HGPIN is considered the most
acceptable PCa precursor by many Pathologists. With a morphology similar to
prostate adenocarcinoma, HGPIN denotes a pre-invasive state to a cellular
hyperplasia of prostatic gland [61]. Not only do PIN and PCa share comparable
morphological features, but they also have similar epidemiological criteria
regarding age and race. A strong relationship is identified between advanced age
and incidence, size, and multifocality of PIN diagnosis. PIN has been reported in
men as early as 20 years of age, however, these findings were associated with to
low-grade PIN [62]. HGPIN and PCa have a high incidental rate in African
American men compared to Caucasian men and other race groups. In contrast, no
significant associations have been found between HGPIN and the increase of free
or total PSA serum level [61-64]. This limitation leads to the conclusion that
prostate biopsy is the only current method of detection and screening for HGPIN.
The specific criteria to distinguish between low and high-grade PIN includes
prominent nucleoli and more atypia in HGPIN [60]. A wide range of intraobserver variability exists with over or underdiagnosis of HGPIN in Pathologists’
reports.
Low-grade PIN glands demonstrate slight epithelial proliferation and crowding
with some irregular spacing. The nucleus criteria includes a slight enlargement
accompanied by a thin membrane and normal chromatin activity. The basement
membrane and basal cell layer are continuous and intact [65].
However, HGPIN consists of benign glands with some architecture abnormalities
in prostate glands acini, the main feature of its diagnosis is nuclear atypia with
close features to cancerous cells rather than normal epithelium.
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Extensive volume and multifocal HGPIN have a high predictive value for
increasing frequency, amount, and severity in the presence of PCa [61]. Both
HGPIN and PCa have a greater chance arising from the peripheral zone. They
demonstrate similar nuclear features and correlate with epithelial dysplasia [65].
HGPIN and PCa share heterogeneous features with multifocal presence. PIN
associated with increased angiogenesis similar to changes that occur with PCa,
which is used as evidence to consider PIN as a PCa precursor. These
characteristics in HGPIN make it one of the mandatory standard diagnosis
remarks in prostate biopsy or radical prostatectomy pathology reports [61].
HGPIN glands display glandular enlargement with four main patterns, tufting
(most common), flat, papillary, or cribriform. Unusual patterns include signet ring
cell, foamy glands, small cell (neuroendocrine), hobnail, and squamoid [66].
There is no clinical significance between patterns. The majority of cases will
demonstrate most of the histological patterns existing at the same time. The acini
are separated by a different amount of stroma. Their characteristic features
include nuclear enlargement and overlap with hyperchromatic evidence add-ons
to the increase of nuclear-cytoplasmic ratio, epithelial hyperplasia, and
amphophilic cytoplasm. The nuclear membrane gets thickened with enlarged
nucleoli. These features are responsible for the PIN basophilic appearance on low
magnification power. The basement membrane is present with disruption to the
basal cells [65]. The HGPIN nuclei are located closer to the gland’s center
compared to the nuclei close to the basement membrane in normal glands [60].
The specific immunohistochemical staining (High molecular weight cytokeratins,
CK5, p63) is used to distinguish between HGPIN and in particular with the
cribriform pattern of Gleason grade 4 in the prostate biopsy (Figure 1.10). PIN
glands show micropapillary form similar to breast micropapillary intraductal
carcinoma with more crowded and piled up nuclei.
The primary incidence of the HGPIN finding and risk of PCa are assumed to be a
50% chance on prostate biopsy. However, later studies showed that the median
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risk of diagnosing PCa after HGPIN detection is about 21% [67, 68]. The
majority of Pathologists agree that the detection of HGPIN on needle biopsy
warrants a follow-up biopsy [69].
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(Figure 1.10) Histopathology digital images for a whole-mount prostate
section with PIN features. (A) Prostate whole-mount section image stained with
high molecular weight cytokeratin immunohistochemical stain (CK) compared to
the same prostate section stained with Hematoxylin & Eosin staining (H & E) (B).
(C) a 10 times power zoom shows the same section area containing glands with
the cribriform type of high grade prostatic intraepithelial neoplasia stained
positive with cytokeratin in the image (C) and (H & E) staining in the image (D).
A high-power zoom of the same section with the area containing PIN, stained
with cytokeratin in the image (E) and with (H & E) stain on image (F). Note PIN
glands stain positive with cytokeratin (dark blue arrow) compared to the negative
stain with prostate adenocarcinoma glands (cyan arrow) in the image (E).
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1.2.7.3

Benign Prostatic Hyperplasia (BPH)

Nodular hyperplasia or BPH is considered one of the benign conditions of the
prostate. It involves an enlargement of the transitional zone and the area around
the urethra due to the proliferation of epithelium and stromal tissue. This
proliferation creates pressure on the prostatic urethra along with prostatic
sphincter. The significant pressure is responsible for a set of symptoms termed
Lower Urinary Tract Symptoms (LUTS). These symptoms include increased
urinary frequency, urgency, weak urine stream with diminished force and size,
incomplete void and nocturia [70]. The transitional zone hyperplasia also
accounts for prostate gland outline deformity. The enlargement of the transitional
zone in the direction of the apex leads to diminishing the anterior fibromuscular
stroma due to stretching and increasing the anteroposterior gland dimension.
Additionally, the peripheral zone is compressed and thinning due to lateral growth
resulting in increasing the gland width [35, 71].
BPH is predominant at an advanced age sharing some similarity with prostate
cancer. However, it is not considered as a PCa precursor. 10% of the BPH cases
are found to be associated with PCa, and they are discovered accidentally during
transurethral prostatectomy resection procedures [72]. An advanced age increases
the risk for BPH and PCa, in addition, both might respond well to androgen
deprivation [73].
BPH usually replaces the entire transitional zone (Figure 1.11) and consist of
multiple, individual, nodules, that differ in size and shape. Grossly, these nodules
are varied between soft, firm or rubbery in consistency and yellowish-gray in
color. There are two subtypes of BPH, depending on predominant tissue
proliferation, epithelial hyperplasia (Figure 1.12), and stromal hyperplasia
(Figure 1.13). Grossly, the epithelial nodules have a spongy like appearance that
bulges on the cut surface which is oozing a pale, white, and watery like fluid. The
predominant stromal BPH consists of fibrous connective tissue and smooth
muscle present with trabeculation or diffuse enlargement with no nodule
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formation. The majority of BPH nodules contain all elements with varying extent
in each nodule.
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(Figure 1.11) Whole-mount prostate formalin block with BPH features and
their digital (H&E) histopathology image. Whole-mount prostate formalin
block (A) shows two yellowish-grayish large transitional zone hyperplasia with a
spongy appearance (blue arrows) adjacent to the Urethra (white arrow) bilaterally.
Right side nodule is more significant than the Left side. The same section
presented in image (B) with Hematoxylin and Eosin stain (H&E) demonstrates a
large transitional zone with benign prostatic hyperplasia (blue arrows) on each
side of the urethral structure (yellow arrow).
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(Figure 1.12) The glandular element of BPH, also known as epithelial element
in the transition zone of the prostate gland. 10X magnification

(Figure 1.13) The stromal element of Benign Prostatic Hyperplasia (BPH).
High power image showing stromal element in the transitional zone of the
prostate gland consists of fibrous connective tissue and smooth muscle.
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1.3

Screening

Improvement in the management and treatment of cancer, in general, is owed to a
unique collaboration between five disciplines including screening and early
detection programs, imaging, surgery, chemotherapy, and radiation. In PCa, the
current detection methods include Digital Rectal Exam (DRE), Prostate-Specific
Antigen (PSA), which is a blood serum testing as initial screening followed by
Transrectal Ultrasound (TRUS) guided biopsies.

1.3.1

Prostate-Specific Antigen (PSA)

Prostate-Specific Antigen (PSA) is a glycoprotein produced by the secretory
epithelial cell in the prostate ducts and acini. PSA is also a serine protease of the
Human Kallikrein family (HK-3). It is responsible for the release of spermatozoa
from the seminal clots by dissolving and the breakdown of gel-forming proteins,
improve sperm motility as well as soften the cervical mucus [74, 75].
PSA is synthesized as a proenzyme (pro-PSA) in normal and other pathological
cells such as hypertrophy or cancer. The Pro-PSA is then secreted into the lumen
of prostate ducts where it gets activated by removing the propeptide chain
followed by inactivation of proteolysis. The active and inactive PSA leaks into the
bloodstream through the capillary basement membrane after passing through the
stroma and epithelial basement membrane. In the blood serum, the inactive PSA
is unbounded and called (free-PSA) while the active form of PSA gets bounded
by a protease inhibitor [76, 77]. Prostate cancer cells were found to produce more
binding protein PSA. This lead to lower free-PSA in proportion to total PSA in
prostate cancer patients [78].
The most commonly used value for PSA cutoff is 4 ng/ml, although this value is
still controversial. The PCa probability with PSA level lower than 2 ng/ml is
found to be around 2%. This probability is increased significantly to 18% with
PSA levels from 2.5-4.0 ng/ml. The possibility of PCa is 22-27% for PSA values
between 4.0 and 10.0 ng/ml, rising to 67% with PSA values more than 10.0 ng/ml
[74]. Studies suggested lowering the PSA cutoff value to 2.5 ng/ml or even
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further to 1.5 ng/ml to improve early cancer detection and a better outcome [79,
80]. However, dropping the cutoff PSA value will lead to increase the sensitivity
and decrease the specificity, leading to an increase in the number of unneccesary
biopsies [77, 80, 81].
Many factors should be measured for the optimum cutoff value for PSA. Factors
such as age, race and medications can have a significant impact on the range of
normal PSA values.

1.3.1.1

Age and Race-Specific PSA Range

The prostate gland tends to increase in size with age, affecting the amount of PSA
produced by normal epithelial cells. As a result, it has been proposed that in men
with no prostate cancer, a different standard reference range for each age group
should be used (Table 1.1) [82, 83]. The PSA value is also affected by various
ethnic and racial groups. Men of African descent were found to have a higher
PSA average compared to those from Caucasian and Asian roots [77, 83, 84].
Since PSA is produced by normal and pathological cells, noncancerous lesions
could affect the level of PSA, but not to the same extent as cancer cells. PSA
could also be influenced by physiological functions like ejaculation, which
increases the PSA level. Prostatitis, infarction, and BPH were found to increase
PSA level. Locally invasive procedures such as prostate needle biopsies were also
are found to increase PSA levels [76].
Medications such as 5-alpha-reductase inhibitor and Finasteride were used in the
treatment of BPH and hair loss respectively were found to lower PSA levels by
50% with minimal effect on PSA produced by cancer cells. These medications
could be used to enhance the efficacy of serum PSA testing to minimize the
number of unnecessary prostate biopsies [85].
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Age

PSA Specific
reference range
(ng/ml)

40-49

0.0-2.5

50-59

0.0-3.5

60-69

0.0-4.5

70-79

0.0-6.5

(Table 1.1) Proposed PSA Age-Specific reference range [82]
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1.3.1.2

Free vs. Total PSA

Currently, the introduction of free PSA to total PSA ratio has improved the
specificity of PSA in predicting and detecting PCa, in particular when total PSA
is in a normal range (below 4 ng/mL) or in the gray zone (4-10 ng/mL). Men with
PCa are found to have a lower percentage of free PSA compared to cancer-free
men. The cutoff value of free PSA percentage around 25% or less was found to
increase the risk of PCa by 95% and decrease unnecessary biopsies by 20% [86].
Other studies suggested adding the age as a considered influence [84]. In the
circumstances of the standard Digital Rectal Exam (DRE) and PSA (4-10ng/mL),
men with 70 years of age and above should use 16% of free PSA compared to
20% in men under 70 years old [87].

1.3.2

Prostate Cancer Diagnosis

Prostate Cancer (PCa) diagnosis is made through histological assessment and
evaluation following a prostate biopsy. Since most PCa arises from the peripheral
zone, it is unusual for PCa to cause any symptoms unless they are locally invasive
to the urethra or if it produced distant metastasis. Before the era of PSA, abnormal
DRE was the only reason for the prostate biopsy. Currently, abnormal PSA alone
is sufficient to warrant a prostate biopsy even though the DRE is normal.
Prostate biopsy is achieved with the aid of Transrectal Ultrasound (TRUS), which
can be used to assess the prostate volume as well as detect prostate lesions for
biopsy. Any suspicious hypoechoic lesion within the prostate gland should be
sampled, even though, not every hypoechoic lesion will be cancer positive. Some
author proposed that only 18% of the hypoechoic lesions will produce positive
tumour sampling [88].
Prostate biopsy was initially performed through a sextant pattern by obtaining one
core bilaterally from the prostate gland base, mid-gland and apex. Increasing the
number of core biopsies with more attention given to the lateral and apex zone
sampling has increased the chance of cancer detection by 31% [89]. Many
research studies focused on increasing the number of sampling cores with the
relation to cancer detection rates. A 10-12 core biopsy pattern provides a balance
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between cancer detection rate and lower morbidity and adverse effect rate [90,
91]. Some authors have reported no extra benefits in cancer detection rate from
increasing core sampling number more than 12 cores [89-91]; however, this is
still controversial.
Despite the chance of improvement in detecting PCa with an extended scheme of
core sampling biopsy, it is still estimated to carry a false-negative rate. The
detection rate in prostate biopsy reaches 39-52% using the assistance of MRI in
high-risk patients after negative detection on previous or initial biopsies [92]. The
challenging task with TRUS biopsy is not only to detect PCa but to identify and
grade cancer for further and more effective management and treatment. Some
studies proposed that only 28% of TRUS biopsy cases were associated with the
same original Gleason score compared to the definite Gleason score found after
radical prostatectomy [93]. The sensitivity of ultrasound to identify prostate
tumour tissue is insufficient, as it depends on cancer volume rather than cancer
grade, and is not consistent for detection of cancer in low-risk men with earlystage PCa [94].
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1.4

Magnetic Resonance Imaging (MRI)

Multi-parametric MRI is used to assess multiple organ parameters in the same
MRI imaging session. The sequences of the mpMRI protocol consist of T2W,
DWI, and DCE. Optional MR spectroscopy imaging can also be added to the scan
protocols [95]. MRI provides a detailed and clear anatomical and tissue image of
the prostate gland structure. It also provides a high intrinsic soft-tissue
informative assessment such as vascular condition, cellularity, and metabolic
evaluation.
Using a surface phased array coil (pelvic-surface coil), the diagnostic accuracy
performance was reported to be 77% overall with a sensitivity and specificity
reaching 71% and 74% respectively [96]. The pelvic surface coil produces an
image showing a respectable detailed anatomical pelvic structure, yet it does not
establish an accurate diagnostic image for smaller sized organs such as the
prostate gland, which may result in an adverse low diagnostic outcome [97].
The introduction of endo-rectal coil (ERC), which suggested a better images
increase the diagnostic accuracy and performance. An ERC captures better and
more detailed gland morphology of the prostate and adjacent tissues, and gives an
opportunity to maximize the utilization of functional mpMRI sequences [96]. An
ERC accompanied with 3 Tesla imaging systems are responsible for increasing
the overall diagnostic accuracy to 97%, sensitivity and specificity 88% and 98%
respectively [96, 98]. Special care must be taken with the use of ERC to avoid or
minimize artifacts during imaging, such as caused by air in the rectal bulb.
Additionally, patient discomfort can cause movement, which leads to
malpositioning and motions artifacts.
Clinical MRI imaging is typically performed with two types of magnetic field
strength fields, either 1.5 or 3 Teslas (1.5T or 3T). Both strengths have been
recognized by radiologists, however, 3T MRI systems increase the signal to noise
ratio (SNR) and spatial resolution, resulting in well developed image and more
enhanced resolution quality [99].
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MRI should be postponed for 6-8 weeks after a prostate biopsy to avoid any
haemorrhage artifacts. Prostate haemorrhage is considered as one of the possible
cancer confounders, mimicking cancer on MRI. The patients are instructed to
abstain from any sexual activity for 72 hours before the scan to increase seminal
vesicle volume and improve cancer detection. Patients are also advised to fast at
least 4 hours and empty their bladder one hour before the MRI scan. Use of
Scopolamine is sometimes required to reduce bowel movement, decreasing
patient discomfort and minimizing artifacts [100].
MRI allows prostate gland assessment with higher spatial resolution and soft
tissue contrast compared to any other imaging modalities.

The three most

relevant MRI sequences in our study were T2-weighted, DCE, and (DWI)
(Figure 1.14).

1.4.1

T2-Weighted Imaging (T2W)

T2W is the main squence used for prostate MR imaging. It is conducted with a
Fast Spin Echo (FSE), also known as a Turbo spin echo (TSE) sequence with
multiple spatial planes, enabling a better assessment of the gland volume than
with other imaging modalities [95]. The T2W sequence creates an image with a
detailed spatial resolution and soft tissue contrast, enabling full evaluation of the
zonal anatomy and adjacent tissues, including the urethra, seminal vesicle,
extracapsular extension, and neurovascular bundles [101]. The high-water tissue
content is represented in the T2W image with a high signal intensity while fat is
displayed with a low signal intensity. In the case of presence of prostate cancer,
water content is diminished significantly leading to a low signal intensity in
contrast to normal adjacent prostate tissue [102].
The multi-planer sequence includes the axial plane, which must be combined with
sagittal and coronal planes. The image generated by the axial sequence typically
includes the bladder dome superiorly until the perineal area inferiorly, and the
coxo-femoral joint borders bilaterally. The sagittal plane enables the evaluation of
the prostate gland posterior surface and its relation to the rectum and the bladder.
The coronal plane, which is slightly oblique along with the main prostate axis,
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allows for a better assessment of the transition and peripheral zone, and in
particular the lateral and anterolateral horns [97].
The normal peripheral zone appears in the T2W sequence as hyperintense,
particularly due to the presence of a significant amount of glandular and highwater content tissue with a clear crescent or horseshoe shape through the midgland section. The peripheral zone is surrounded by a prostate capsule, which
appears as a thin, full hypointense layer, that circles the whole gland. The prostate
capsule has a substantial clinical significance, as it is used as a landmark in
staging PCa [101]. Cancer in the peripheral zone is characterized by an oval or
nodular shape focus with low-signal intensity. The sensitivity in detecting PCa in
T2W reaches more than 90% with Gleason score of 7 and higher, and decreases
markedly with Gleason score lower than 6 [100].
The Central and Transition zones are hard to distinguish when there is no
evidence of BPH presence. The differentiation of the central zone could reach
80% with current MRI systems [103].
The transition zone consists of less glandular tissue with low water content
compared to the peripheral zone. The internal gland, which forms from the
transitional and periurethral zone is categorized by intermediate signal intensity,
which increases the challenge for detecting cancer in the transitional zone due to
signal overlapping of tumours and BPH. The central gland is surrounded by a
thin hypointense layer isolating it from the peripheral zone [100].
The transition zone in the presence of nodular hyperplasia shows heterogeneous
signal intensity depending on the nodules’ consistency. Two types of nodules can
be found in the transition zone, glandular and stromal nodules. Glandular nodules
represent the more common type. It appears as a homogeneous high signal
intensity due to high fluid content with a thin layer of the hypointense capsule.
The second type is a stromal nodule, which has a homogeneous low-signal
intensity surrounded by a fine hypo-intense capsule. The stromal nodule is more
relatively challenging to identify due to its distinct variation [96]. The malignant
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tissue in TZ appears homogeneous with vague or blurred margins giving an
erased charcoal sign, lenticular, or water drop shape [104].
Identifying PCa in the central zone with T2W imaging is quite challenging [105].
It appears as a collection of tissue separating the transition zone from the
peripheral zone on an axial view with low-signal intensity compared to the outer
region. The central zone tissue is commonly pushed laterally towards the
peripheral zone by glandular hyperplasia of the transitional zone. The coronal
view sequence illustrates the central zone as a triangle or tear-drop-shaped
appearance ranging from seminal vesicle to verumontanum area [105].
The anterior fibromuscular stroma (AFMS) is the most anterior structure of the
gland with a crescent or wedge-shaped appearance. It is characterized by
homogenous, marked hypointense signal on T2W, which is best seen in an axial
view sequence. Cancer involvement in AFMS is signified by a high signal
intensity rounded in shape and external protrusions that affect gland symmetry
and sometimes prostate capsule continuity in the case of external prostatic
extension (EPE). Due to its heterogeneous appearance, a normal central zone
tissue could mimic cancer on T2W and ADC imaging [96, 106].
The coronal view sequence gives excellent detail of the seminal vesicles, and has
a variable signal intensity that relies on fluid volume. Aging has an adverse
physiological effect on fluid volume inside the seminal vesicle leading to a
decrease in signal intensity. Cancer involvement in the seminal vesicles is
characterized by thickening of its wall, asymmetric shape appearance, focal or
diffuse low signal intensity, and enlarged ejaculatory ducts [107-109].
The sagittal view provides an excellent imaging tool to assess the bladder neck, a
full length of the prostatic urethra, seminal vesicle and its relationship to the
rectum and Denonvilliers's fascia. This provides a practical tool for PCa staging.
Cancer mimickers in T2W images include the central zone, stromal BPH,
ejaculatory ducts, haemorrhage, and chronic prostatitis.
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1.4.2

Diffusion-Weighted Image (DWI) and Apparent Diffusion
Coefficient (ADC)

The diffusion-weighted image (DWI) sequence is based on Brownian motion of
water molecules in tissues, which is affected by tissue temperature and by degree
of cellularity [110]. The diffusion of fluid occurs from a high concentration zone
to a lower concentration zone, and is controlled by tissue thermal energy and
cellularity. The DWI sequence provides the ability to assess the microarchitecture of the imaged tissue [111]. The coefficient “b” is the determining
factor of the diffusion sequence. The level of sensitivity of water molecules
weighted diffusion is directly proportioned with “b”.

The “b” coefficient is

affected by the diffusion parameters, which include distance, intensity, and
duration between two tissue gradients. Thus, DWI will be more sensitive to
tissues with a higher diffusion coefficient [96, 101]
The quantitative assessment of the reconstructed DWI image is used to generate a
visual map called the Apparent Diffusion Coefficient (ADC). The ADC map,
expressed in units of 𝑚𝑚2 /s, is calculated using the “b” coefficient, which
represents the degree of water molecules diffusion in the targeted tissue [96]. The
ADC map establishes an estimated average value of each voxel in the imaged
region and is displayed as an opposite contrast to the captured DWI image. This
process assists in eliminating the T2 shine-through effect as ADC measures the
degree of diffusion independent from the T2 shine influence. [95, 112].
Water diffusion in healthy prostate tissue is captured as a low signal intensity due
to low or regular cellularity due to free water diffusion. The image is depicted as a
hyperintense value on ADC. In contrast, cancer tissue is associated with crowded
small glands, and cells with a larger nucleus to cytoplasm ratio, a limited amount
of stroma between glands, reduced extracellular space, and abnormal
parenchymal tissue structure. These changes diminish water molecule diffusion in
tissues, and result in a high signal intensity on DWI, which is converted to a
hypointense value on an ADC image [95, 101]. DWI and ADC images in addition
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to T2W could provide an extra quantitative assessment of prostate tumour
behavior and aggressiveness [113].

1.4.3

Dynamic Contrast-Enhanced (DCE)

PCa is found to be associated with a new vascular formation with high vascular
density and permeability in a process called neoangiogenesis. This blood supply
provides the necessary nutrients to tumour cells [114]. DCE-MRI is a functional
imaging method with the ability to assess the vascular supply and microvascular
structure of the tissue in a given zone by capturing the tissue enhancement after
intravenous administration of a contrast agent. The DCE imaging procedure takes
approximately 5-10 minutes to complete. A fast T1W sequence is required to
acquier multiple serial images within a short time interval before and after
contrast injection. T1W images will establish a baseline evaluation of the tissue
during contrast injections to distinguish the contrast influx to the prostate gland,
and post-injection, to estimate the uptake and washout time of the contrast. These
multiple scans provide images of the prostate tissue perfusion for assessment
[115]. The DCE images are obtained with high temporal resolution and a 3D
acquisition mode.
The DCE image is generated by injecting rapidly a contrast agent of lowmolecular-weight gadolinium chelate at a rate of 2-4mL/S followed by a saline
flush [101]. The contrast agent molecules will diffuse into the extracellular
extravascular space (interstitial space), termed as the leakage space. Abnormal
neovascularization and reconstruction, which accompany the prostate tumour, will
have a stronger vascular leakage, resulting in the prostate tumour having a
quicker, more intense contrast enhancement compares to the normal adjacent
tissues followed by rapid washout before surrounding tissue [96].
There are three methods available for assessing DCE images, qualitative, semiquantitative and quantitative. The qualitative assessment approach is based on the
visual analysis of the potential cancer area with observation of the rapid regional
significant enhancement and early washout of the contrast agent compared to the
adjacent tissue. This method is subject to inter-observer experience and variability
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with the least standardization capability. BPH, transitional zone, and
inflammation could be responsible for relatively high enhanced image on DCE
sequence and quicker washout compared to the rest of the gland tissue, but not to
the same extent as PCa [102, 116].
The semi-quantitative approach utilizes the time and intensity curve in addition to
the same principle used in qualitative assessment including the time for
enhancement and washout. The time/intensity curve estimates the time to obtain
maximum peak enhancement, the slope of the curve, wash-in or wash-out times.
Three types of time/signal intensity curves are commonly generated with a
software aid. The persistent type 1 curve shows a clear evidence of the constant
progress of enhancement after the initial peak. Type 2 curve, which is named a
plateau, shows a curve that flattens after the initial peak. Type 3 curve is named
the decline, and is characterized by rapid decline of the curve after the initial peak
[117, 118]. Prostate tumours are more likely to be associated with a type 3 curve,
but can produce type 1 and type 2 curves to a lesser extent [119].
Quantitative DCE image assessment utilizes multifaceted methods including
pharmacokinetic parameters such as the volume transfer constant (𝐾 𝑡𝑟𝑎𝑛𝑠 ), which
evaluates the contrast agent influx from blood vessels and capillaries into the
interstitial space, which is extracelluler and extravaculer. (𝐾 𝑡𝑟𝑎𝑛𝑠 ) is influenced
by blood flow, vascular permeability and surface area [120]. The reverse reflux
rate of contrast agent from the interstitial space back to the vascular stream is
(𝐾𝑒𝑝 ), and (𝑉𝑒 ) represents the extracellular, extravascular volume fraction and are
related thus: 𝐾𝑒𝑝 = 𝐾 𝑡𝑟𝑎𝑛𝑠 /𝑉𝑒 [117]. Many software applications have been
developed to generate more accurate and quantitative DCE map parameters to be
used in developing more standardized assessment guidelines in the evaluation of
PCa from DCE images. Prostate cancer will produce an increase in 𝐾 𝑡𝑟𝑎𝑛𝑠 and
𝐾𝑒𝑝 . The current method of choice is the quantitative assessment of DCE images,
despite its high complexity compared to semiquantitive assessment [117].
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(Figure 1.14) In-vivo prostate multiparametric MRI and its corresponding
histopathology digital image. (A) Axial T2W image with an area of
hypointensity on the right posterolateral aspect of prostate gland (light blue)
contour. (B) Dynamic contrast-enhanced image. (C) ADC map with hypointensity
in the same region. (D) Histopathology digital image for the whole-mount
prostate section with adenocarcinoma features in same region (brown) contour.
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(E) 10X image of the affected area showing Gleason grade 4 (G4)
adenocarcinoma. (F) High power view for the affected area (rectangular) with a
G4 cribriform pattern.
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1.5
Prostate Imaging Report and Data System (PIRADS)
The emergence of MRI as a useful tool in detecting and localizing prostate cancer
was accompanied by an initial lack of standardization in interpreting of this
imaging data between radiologists with similar earlier challenges faced with
breast mammogram. Thus, there was an urgent need to develop an assessment
approach to be widely adopted by experts to improve the quality of reporting,
create a better standardization and reduce inter-observer variability.
Multiple assessment methods have been introduced to evaluate prostate mpMRI.
One of the preliminary methods was assessing the suspected lesion on a binary
scale whether it is positive or negative for malignancy [121]. Based on the
number of sequences marked as positive, the suspected lesions were asigned a
score of low, intermediate and high. Despite the simplicity, this approach was not
popular due to the inability of addressing the variability of degree of abnormality
observed in the MR image sequences [122].
Recently, the Prostate Image Report and Data System (PI-RADS) has gained
international popularity since it was introduced by the European Society of
Urogenital Radiology, followed by publishing a guideline in 2012 [123]. They
aimed to develop a clinical guideline that focuses on the three optimal diagnostic
technique for detecting, staging, node and bone involvement.
To assess prostate mpMRI images using a PI-RADS score, prostate images should
be acquired using a high-field scanner with 1.5 Tesla (1.5T) as a minimum field
strength accompanied by endo-rectal and body phase array coils to yield a high
signal to noise ratio. An endo-rectal coil could be optional with field strength of 3
Tesla [124].
The T2W image using turbo-spin-echo (TSE) is the main method for prostate MR
imaging as it provides a highly detailed image of the prostate anatomy and
surrounding tissues with visually recognizable zonal morphology. T2W images
are acquired with axial, sagittal and/or coronal sequences [124], and a T1W image
is also highly suggested to rule out any intraprostatic haemorrhage from a prior
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biopsy or inflammatory reactions. The T1W image could also be helpful in
assessing parailiac and regional lymph nodes enlargement, suggesting a metastatic
disease [124].
The PI-RADS classification of T2W is based on zonal anatomy. Two separate
schemes are endorsed for different zonal anatomy as the contrast varies between
peripheral zone and central gland (Table 1.2-1.3). Also, any involvement of the
bladder neck, seminal vesicles invasion or extra-prostatic extension must be noted
[125, 126].
The PI-RADS interpretation of DWI is based on images acquried with a high bvalue (b≥800s/mm2 ) with corresponding apparent diffusion coefficient map. Each
lesion is assessed with a score 1-5 according to signal intensity and localization
[127].
Any increased signal in DWI aquired with a high b-value not accompanied by a
focally reduced the signal in the ADC maps is assigned a Score of 1. Diffuse
hyperintense signals on DWI with a reduced signal on a corresponding ADC map
is assigned a score of 2 (lesion cannot be delineated). Score 3 is assigned to a
diffuse asymmetrical or unilateral high intense signal on the high-b-value image,
which is accompanied by a decreased signal on a corresponding ADC image.
Focal lesions that are isointense on DWI with a high b-value and a signal
reduction on a corresponding ADC map are assigned a score of 4. The focal
significant reduction on an ADC map with a focal hyperintense signal in a
corresponding DWI image with a high b-value (b≥800s/mm2 ) is assigned a score
of 5 (Table 1.4) [123, 124].
The PI-RADS is used to assess each mpMRI image individually with a score
range from 1 to 5. The assessment followed by an overall score varies from 1 to 5.
Each area and suspected lesion in an image generated by the different sequences
should be evaluated separately with a scoring between 1 and 5. The total overall
rating is then calculated based on a number of lesions, locations and each lesion
score with the possibility of the presence of extraprostatic extensions. An overall
score ranging between 1 and 5 characterizes the probability of the presence of a

48

clinically significant tumour. Transitional zone assessment must be performed
separately from the peripheral zone [122, 123]. The PI-RADS assessment must
include the seminal vesicles, prostate capsular involvement or any sign of
potential or compact evidence of extraprostatic extension [123].
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Score

Criteria

1

Uniform high signal intensity (SI)

2

Linear, wedge shaped or geographic areas of lower SI,
not well demarcated

3

Intermediate appearances not in categories 1-2 and 45

4

Discrete, homogeneous
confined to the prostate

5

Discrete, homogeneous, low SI focus with EPE,
invasive behaviour or mass effect on capsule (e.g.
bulging)

low

signal

focus/mass

(Table 1.2) PI-RADS scoring system classification criteria for T2W image
assessment for the peripheral zone [123]

Score

Criteria

1

Heterogeneous TZ adenoma with well defined margins
(organised chaos)

2

Areas of more homogeneous low SI, well defined
margin, originate from TZ/BPH

3

Intermediate appearances not in categories 1-2 and 4-5

4

Areas of more homogeneous low SI, ill defined (erased
charcoal)

5

Same as 4, involving the AFS or anterior horn of PZ,
lenticular or water drop shaped

(Table 1.3) PI-RADS scoring system classification criteria for T2W image
assessment for the Transition zone [123]
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Score

Criteria

1

No reduction in ADC compared with normal glandular
tissue. No increase in SI or any high b-value image
(≥b800)

2

Diffuse, hyper SI on ≥b800 image with low ADC. No
focality however, linear, triangular or geographical
features are acceptable

3

Intermediate appearances not in categories 1-2 and 4-5

4

Focal area(s) of reduced ADC but iso-intense SI on high
b-value images (≥b800)

5

Focal area/mass of hyper SI high b-value images (≥b800)
with reduced ADC

(Table 1.4) PI-RADS scoring system classification criteria for Diffusion
Weighted Imaging (DWI) image assessment [123]
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(Figure

1.15) Twenty-seven regions of interest for the standardized PI-RADs

scheme [128], a: anterior, as: anterior stroma, p: posterior, R: right, L: left. SV:
seminal vesicles.

PI-RADS
Score

Interpretation

1

Benign, highly unlikely for malignancy

2

Most probably benign or unlikely for
malignancy

3

Intermediate or equivocally

4

Likely or probably malignant

5

Highly suspicious of malignant

(Table 1.5) Interpretation of PI-RADS scoring assessment [124, 128]
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1.6

Rationale

Our study aims to gain a better understanding of non-cancerous pathological
lesions in prostate gland and their relationship to mpMRI signal that could be
mistaken as a potential cancer signal on MRI.
This may help increase cancer detection accuracy and reduced false positive
detection of prostate cancer.

1.7

Hypothesis

Atrophy, PIN, and BPH are the main non-cancerous pathology that could mimic
cancer like signals on mpMR images due to their morphological similarity with
adenocarcinoma.

1.8

Specific Aim

The objective of the study is to test and examine non-cancerous pathology lesions
and their subtypes that could raise a false positive cancer like signals on mpMRI.
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Chapter 2

2

Materials and Methods

This study was approved by the Human Subject Research Ethics Board London
Health Sciences Center, (LHSC), and University of Western Ontario, London,
Canada). A written informed consent was obtained from each patient before a
non-clinical standard set of in vivo prostate gland scan. Images were taken two to
three weeks in advance of surgery.

2.1

Materials

A total of 19 patient were enrolled in the study. Patients who participate in the
study have been previously diagnosed with prostate cancer through prostate
biopsy. Prior to prostatectomy, a multi-modality set of images including an in vivo
multiparametric Magnetic Resonance images (mpMRI) were acquired from each
participant using a 3 Tesla MRI scanner (GE Discovery MR750, GE Healthcare,
Waukesha, WI) [129] with the use of an endorectal coil (Prostate eCoil; Medrad,
Warrendale, PA) surrounded by barium sulfate suspension in a sheath [129]. The
mpMRI included high-resolution T2W images for diagnostic assessment, also to
allow registration to other modalities, Dynamic Contrast Enhanced (DCE) and
Apparent Diffusion Coefficient (ADC) images [130]. The in vivo mpMRI images
were obtained after the biopsy and before surgery. The mpMR Imaging was
performed 19 weeks (± 8 weeks) following the biopsy. This period was to allow
the prostate gland a recovery period to avoid haemorrhage interference with the
analysis of the images.
A strict patient inclusion and exclusion criteria allowed for the collections of the
radical prostatectomy specimens from 19 cases. Patient inclusion criteria were as
follows: the patient must be at least eighteen years of age and have a confirmed
clinical diagnosis of PCa histologically, clinical classifications of the tumour
grade between T1 and T2 by trans-rectal ultrasound (TRUS) guided biopsy, and
radical prostatectomy as the choice of treatment. Patient Exclusion criteria were:
any use of 5-alpha reductase inhibitors in the past 6 months prior to study
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enrolment, any prior therapy for PCa, any contraindications to perform and
acquire the preoperative set of MR imaging with contrast as renal functions
impairments, sickle cell disease or any other type of anemia, and allergy to the
contrast agents or any source of artifact in the pelvis (e.g. hip prosthesis).
The T2W imaging was performed with a two-dimensional (2D) and threedimensional (3D) fast spin-echo sequence (repetition time msec/echo time
msec,6050/163; bandwidth, ±31.25 kHz; two signals acquired; field of view, 14
cm; section thickness 2.2 mm; matrix -384 × 256; 40 slices) and (2000/148.5;
bandwidth, ± 125 kHz; one signal acquired; field of view, 14cm; slice thickness,
1.4 mm; matrix, 320 × 192; 84 slices) for 2D and 3D T2W respectively. The T1
weighted images were acquired with the 3D spoiled gradient-recalled echo
(5.6/2.1; bandwidth, ±31.25 kHz; two signals acquired; field of view, 14 cm;
section thickness, 2.8mm; matrix, 256 ×192; 42 sections; flip angle, 15°;7
volumes acquired at 90 sec/volume) [130]. The T1W imaging was performed
after administration of gadopentetate dimeglimine (Magnevist; Bayer Healthcare
Pharmaceutical, West Haven, Conn) intravenously [130]. The dose of
gadopentetate dimeglimine was 0.1 mmol per kilogram body weight with
injection rate of 4 ml/sec followed by 20ml of saline flush. The radical
prostatectomy followed in vivo imaging. The resected prostate specimens were
fixed in formalin for 72 hours before fiducial insertion, ex vivo MR imaging, and
histopathology processing (Figure 2.1).
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PCa diagnosis via
prostate biopsy

A set of in vivo
mpMRI

Surgery

Ex vivo MRI

Fiducial Insertion
and Processing
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Histopathology
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Digital Contouring
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Registration
Between (HDI)
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In vivo mpMRI
Radiology
Assessment and
contour

(Figure 2.1) Overview of the steps in our method used in prostate specimen
processing.
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2.2
2.2.1

Methods
Fiducials Processing

Before obtaining ex vivo prostate MR images, two sets of 10 standard shape
fiducials markings were applied to the prostate gland. The aim of this nonanatomical markings was for them to be visible in the ex vivo MR and digital
histology images. The fiducials were required to be able to endure the heat and
the tough chemical treatment through gland grossing and histology processing
without any distortions or damage to the tissue. In contrast, these fiducials should
not have any impact on pathologists’ assessment. This was ensured as any
alteration to pathology assessment will have a significant impact on post-surgery
patient care and management.
The internal fiducial markers consisted of three cotton threads soaked in blue dye
designed for tissue marking (Triangle Biomedical Sciences, Durham, NC) and
1:40 gadopentetate dimeglumine, which enabled visibility and identifications of
the fiducials on T1 weighted MRI [131]. The internal fiducials applications were
completed with the assistance of 18G cannula and stylet with a Quincke-type
point (Figure 2.2). The cannula with a stylet was designed to perform a clear
tissue separation to avoid any tissue damage during the insertion processes. The
cannula and stylet were inserted into the prostate gland from the base and exit at
the apex with an optimal target to be within one centimeter posteriorly to the
anterior urethral opening. Strict measurements were applied with caution to keep
the cannulas at a fair distance from the urethral structural and openings to avoid
any clinical assessment alteration or aggressive treatment methods for follow up
management due to possible higher tumour staging diagnosis. Following the
insertion of total three 18G cannulas and style, two on the right prostate lobe and
one on the left lobe, the stylets were then removed, and a fair length cotton thread
was inserted through each cannula. The free part of threads were soaked in blue
dye and gadolinium. Following the cotton thread insertion with the blue dye, the
cannula and cotton thread were pulled together outside the prostate tissue leaving
the free soaked thread part with the blue dye and Magnevist within the prostate
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tissue (Figure 2.3). The applied dye tissue marking enabled localization during
digital histopathology analysis, and the gadolinium allowed localization in the ex
vivo MRI. The cotton threads were removed after whole gland MR imaging and
before specimen slicing to avoid any tissue disruptions during specimen slicing
[132].
Cylinder-shaped surface-mount fiducials were extracted from a formalin fixed
lamb or pig kidney cortex via 16G biopsy needle (the same model used in a breast
biopsy) (Figure 2.4). After successful extraction, they were completely immersed
in 1:40 gadopentetate dimeglumine and 10% buffer formalin for a minimum of at
least 20 minutes to ensure the completion of infusions. The fiducials were firmly
fixed to the prostate surface using 411 Loctite ethyl cyanoacrylate adhesives
(Loctite 411; Henkel, Dusseldorf, Germany) (Figure 2.5). Loctite 411 does not
interfere or generate any tissue damage during the cutting processes.
Furthermore, Loctite 411 is sufficiently tough enough to survive the heat and
chemicals through histology processing, preventing the external fiducial from
deteriorating or disruption during the rough processing methods. The following
step includes three fiducials applied on the posterior surface with one fiducial on
each side with a 45° angle, and the remaining fiducial was applied centrally. On
the anterior surface, three parallel fiducials were attached with two on the left side
and one on the right. A fourth fiducial was placed diagonally from the right
anterior to left posterior apex to base. Thus, a total of seven fiducials were
mounted on the surface of the prostate [130-133].
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a
Rt

Lt
b

(Figure 2.2) Prostate gland with three 18G cannulas with inserted threads
after removing the style. (Rt) right side, (Lt) left side (a) 2 threads on the right
side and (b) 1 on the left side of the prostate gland.

Rt

Lt

(Figure 2.3) Prostate gland after threads soaking in Magnevist & dye,
followed by removing 18G cannula leaving threads inside the glands.
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(Figure 2.4) The external fiducials obtained from a pig kidney by using breast
biopsy needle
A

b
c

Rt

B

a

b

b

Lt

Lt

Rt

(Figure 2.5) The anterior and posterior surface of prostate gland postfiducials application. (A) The anterior surface of prostate gland post fiducials
application (pig Kidney) using 411 Loctite ethyl cyanoacrylate adhesives. Total of
4 fiducials, (a) 2 fiducials on the left side, (b) 1 placed diagonally, and (c) 1 on the
right side. (B) Prostate gland posterior surface with a total of three fiducials (pig
kidney) applied using 411 Loctite ethyl cyanoacrylate adhesives.
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(Figure 2.6) Internal and external fiducial marking in formalin block and
histopathology image. (A) Image of whole-mount prostate formalin blocks
surrounded by the remnant of agar after prostate gland slicing and its
corresponding (H&E) digital histopathology image (B). A total of 10 fiducial
markings are clearly visible; 3 internal (black squares) with 2 on the right side and
one on the left. A total of 7 surface mount fiducials (white arrows on formalin
block and deep blue arrows on digital histopathology image), 4 on the anterior
surface and 3 on the posterior.

(Figure 2.7) High power digital histopathology images showing 3 visible
inked internal fiducials marking (3 black squares on Fig: 2.6, B) with deep blue
ink in 3 internal fiducial markings which were used as landmarks for prostate
image reconstruction and registrations.
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2.2.2

Ex-vivo MR Imaging

The ex vivo MR imaging was performed following the placement of fiducials
marking. The whole gland was placed and fixed inside in a large glass syringe to
prevent any movement during the MR scan. The glass syringe was filled with
Christo-Lube MCG 1046 (Lubrication Technology, Franklin Furnace, OH). The
Christo-lube is invisible in MR images, which gives zero signals to the
surrounding regions of the gland. This provides a black background in the image
and minimizes magnetic boundary artifacts at the prostate gland border. The MR
images were acquired by an MR750 system (GE Healthcare, Waukesha, WI),
using a carotid coil instead on endorectal coil in in-vivo MRI scan, T2W (3D fast
spin echo; TR/TE:2000/148.5ms; bandwidth, ±125kHz; three signals acquired;
field of view, 14 cm; slice thickness, 0.4mm; matrix 320×192; 160 sections; 25
minutes), and T1 weighted signal (3D spoiled gradient-recalled echo; TR/TE:
6.5/2.5ms; bandwidth, ±31.25 KHz; eight signals acquired; field of view, 14 cm;
section thickness, 0.4 cm; matrix 256×192; slice; flip angle, 15°; 25 minutes)
protocols [129, 132].

2.2.3

Specimens Slicing, Histopathology Processing, and Digital
Contouring

This process was initiated after the removal of the prostate apex. The aim is to
remove the prostate apex including the entire anterior urethral opening with at
least 1 cm in thickness. The pathologist determined the plain of the first cut by
visual assessment.

Three pins were inserted, which were used for surface

orientations during surface cuts using slotted forceps (ProCut; Milestone Srl,
Sorisole, Italy) with design adjustments to avoid any lateral motions between the
upper and lower forceps plates during cutting processing [131, 132].
Following the apex cut, the specimen was positioned in a square box with the cut
surface facing the bottom of the box. The box was filled with liquid agar and
cooled to 4°C. The whole block was sliced with a rotator blade cutter (GC-9
Slicer) measuring 4.4 mm thickness from the anterior cut aspect (Globe Food
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Equipment, Dayton, Ohio) [131]. This thickness enabled simple registrations with
MRI images since they were obtained with a 2.2 mm image slice thickness. The
4.4 mm histological thickness also resisted fragmentation or tissue rolling during
handling and histology possessing. An average of three to five whole-mount
sections per specimen were completed depending on prostate volume and shape.
The clinical histopathology processing protocols followed the base cutting, which
included whole mount paraffin block, microtome cutting at 4 µm thick sections
from each whole-mount block and staining with hematoxylin and eosin stain. The
slides were then digitally magnified at 20X (0.5µm/pixel) using the brightfield
slide scanner (ScanScope GL; Aperio Technology, Vista, CA, USA). Digital
histopathology images were contoured with a color-coded scheme to identify
various types of Gleason grades and scores as well as other non-cancerous
abnormalities such as PIN and Atrophy (Table 3.1). The contouring was
completed with the use of Cintiq 22-inch HD widescreen computer monitor,
which included an enabling pen for fine drawing (Wacom Co, Japan) and image
scope software (Aperio Technology, Vista, CA, USA) (Fig 2.8). The image
contouring process was done under the supervision of two genitourinary
pathologists, which their approval is required before submission to allow for the
next step of registrations to be completed.
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G3

G4+3

PIN

G4

G4+5

EPE

G5

G5+4

Positive Margin

G3+4

G5+3

Atrophy

(Table 2.1) The color coding scheme used for contouring cancer and noncancerous lesions on digital histopathology images. (G3) Gleason grade 3, (G4)
Gleason grade 4, (G5) Gleason grade 5. For the areas, which included more than
Gleason grade with difficulty to contour separately. Thus, we combined the two
or more grades together, with respect to dominant grade to be called first. For
example, the G3+4 contour present area of two great complexes enough to
separate them, with the G3 is the dominant grade in this area. PIN: Prostatic
Intraepithelial Neoplasia, EPE: Extra-Prostatic Extension.
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C

G3
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G3+4
G4+3
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PIN

(Figure 2.8) Histopathology digital images for a whole-mount prostate section
showing several contours with there color-coded scheme. (A) Prostate wholemount histopathology image with color-coded contours for various types of
cancer grade and non-cancerous abnormality. (B) 10X power zoom showing
section with area contoured with (G3) Brown-Gleason grade 3, (G3+4) GreenGleason grade 3+4, (EPE) cyan-Extra-Prostatic Extension. (C) reveals a highpower zoom 20X with G3, G3+4, and EPE.
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Before full registrations, the in vivo mpMR images were assessed and contoured
independently by four radiology observers. These observers had various levels
and years of experience in prostate cancer assessment and diagnosis with mpMR
imaging. The years of experience varied from five and six years with observer A
and B respectively, to two and half years with observer C and D. These observers
were aware that all patients had a biopsy confirmed PCa. However, they had no
previous exposure to the histopathology diagnosis reports or evaluation for each
individual case. They contoured unregistered T2W, DCE, and ADC MR images
sequences separately using Version 1 of the Prostate Imaging Reporting Data
System (PI-RADS) score system. The observers delineate lesions with a score
from three to five: equivocally (3), likely (4) and very likely (5) to be a malignant
tumour area. In this study, we only considered the same areas outlined by the
radiology observers in the three-consecutive unregistered sequence of mpMRI,
T2W, DCE and ADC. The PI-RADS score used in this study is the overall
assessment score for each lesion in the three-previous consecutive sequence of
mpMRI.

2.2.4

Registration

Initial registration was performed using the 3D Slicer viewing software between
digital histopathology images and 3D ex vivo MR images with the aid of applied
fiducials markings [132]. An interactive digital technique was developed in our
lab for deformable registration of 3D ex vivo MRI and in vivo mpMRI to high
resolution 3D in vivo T2W MR images with histopathology [133, 134]. Using a
rigid method of registration and the anatomical homolog landmarks (e.g., Urethra,
Verumontanum,

cystic

atrophy

spaces,

benign

prostatic

hyperplasia,

calcifications) the registration error was ≤ 2 mm on average. This interactive
digital technique allowed navigating simultaneously between the mpMRI
sequences (T2W, DCE, and ADC) and the contoured histopathology. To avoid
any confusion or registration errors, we excluded any false positive MRI contours
adjacent to PCa region on the histopathology digital images.
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Chapter 3

3

Results
Analysis of MRI Contoured Areas

3.1

(Figures 3.1-3.4) show examples of contoured mpMRI images by the four
radiology observers and the corresponding histopathology images. These four
figures illustrate four different patient cases of the 19 cases analyzed in this study.

A

B

C

D

(Figure 3.1) True Positive mpMRI contour correlated to Gleason grade 3
adenocarcinoma on histopathology image. (A) Histopathology image showing
a contoured area (gray arrow) for Gleason grade 3. (B) True positive areas on
T2W MRI image contoured by the 4 observers, (C) contoured on DCE MRI
image, and (D) contoured on ADC map and their corresponding area on histology
with Gleason grade 3, and Gleason scores 6.
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A

B

C

D

(Figure 3.2) False Positive mpMRI contour correlated to the area with
atrophic glands. (A) A false positive area on T2W MRI image contoured by one
observer (gray arrows). (B) Contoured on DCE MRI image, and (C) contoured on
ADC map. The corresponding area on histology shows atrophic glands change on
Histopathology image (D).

A

B

C

D

(Figure 3.3) False Positive mpMRI contour correlated to the area with BPH.
(A) A false positive area on T2W MRI image contoured by one observer (gray
arrows). (B) Contoured on DCE MRI image, and (C) contoured on ADC map.
Their corresponding area on histology displays BPH on Histopathology image
(D).
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A

B

C

D

(Figure 3.4) False Positive mpMRI contour correlated to the area with
prostatic intraepithelial neoplasia (PIN). (A) A False positive area on T2W
MRI image contoured by one observer (gray arrows). (B) Contoured on DCE
MRI image, and (C) contoured on ADC map. The corresponding area on
histology shows PIN on Histopathology image (D).
The graphs in (Figure 3.5-3.6) demonstrate the analysis results of the 37 MRI
contoured areas. After corresponding these radiology contoured areas to the
corresponding histological regions. This analysis shows the number of each noncancerous lesion (PIN, Atrophy, BPH, normal histology) and their PI-RADS
score assessed on MRI.
The first radiology observer (A) had six years of experience in prostate MRI
imaging assessment and PCa diagnosis. This observer contoured seven suspicious
lesions in MRI, which were identified on histology to be false positive areas.
After corresponding these contoured MRI areas, histology images revealed three
lesions of PIN with a PI-RADS score 4. Of the other three atrophic areas, two
were given a PI-RADS score 3 and one a PI-RADS score 5 on the contoured
unregistered MRI images.
The second radiology observer (B) had five years of experience in prostate MRI
assessment. This observer contoured a total of fourteen areas in the MRI images,
which were a false positive. Histology images revealed that four of these areas
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were PIN, two lesions were marked as PI-RADS score 3, another area was labeled
as PI-RADS score 4 and one as PI-RADS score 5. Histology images showed that
atrophy was represented in six MRI susceptible lesions. Three areas were assessed
as PI-RADS score 3, and the other three were given PI-RADS score 4. BPH was
found in three areas, two of them were PI-RADS score 3, and one was a PI-RADS
score 4. There was one area assessed as a PI-RADS score 3, which the histology
revealed to be a non-pathological central zone structure.
The third radiology observer (C) had two and a half years of experience in
prostate MRI assessment. This observer contoured a total of seven areas on MRI,
which were false positive areas. Corresponding histology images of contoured
MRI areas revealed that five areas were PIN and two were atrophic regions. Of
these five areas, two had a PI-RADs score 3, and two had PI-RADs score 4, and
one area with PI-RADS score 5 assessments. The PI-RADs score for the two
atrophic areas were assessed as score 4 and 5.
The fourth radiology observer (D) also had two and a half years of experience in
prostate MRI imaging. This individual contoured a total of nine regions, which
were false positive areas. Corresponding histology images to MRI contoured
areas with PI-RADS score 3 and above revealed that four areas were PIN. Of
these four areas with PIN, one had a PI-RADS score 3, two had a score of 4, and
one area had a score 5. Two areas with PI-RADS score 3 and 4 were regions of
atrophy. BPH was in one contoured area with PI-RADS score 4, and two areas
with normal structure were contoured on MRI as PI-RADS score 4 and 5.
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Figure 3.5. Histogram demonstrate the total PI-RADS scores assessment
performed by the 4 radiology observers and their corresponding histology
findings. Histogram demonstrate the total PI-RADS score assessment contoured
by four radiology observers on three functional MRI image sequences (T2W,
DCE, ADC) and their corresponding non-cancerous lesions on digital
histopathology images (n=19).
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Figure 3.6. Histograms of the frequency of the PI-RADs score of contoured areas on
mpMRI by each observer separated by the histologically identified non-cancerous
lesions on HDI.
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3.2
MRI

Analysis of Histology Areas Corresponding to

(Table 3.1) shows a summary of the analysis of the histology images, which
corresponded to MRI contoured areas. The graphs in (Figure 3.7) display the
frequency of each non-cancerous lesions (PIN, Atrophy, BPH, normal histology)
and their PI-RADS score assessment.
The 23 digital histology images showed that PIN was found in 10 areas. With 8
areas demonstrating solitary PIN and 2 areas with PIN admixed with other noncancerous lesions. Of the 8 areas with a solitary PIN, 2 areas were found with a
flat pattern, 2 areas with a papillary pattern, 2 with tufting and 1 with a cribriform
pattern. There are 2 areas found with 2 patterns mixed between flat and tufting
and 1 area mixed between papillary and cribriform. The remaining 2 areas
admixed with other non-cancerous lesions were found to be a flat pattern,
admixed with simple atrophy. The other area was a flat and tufting pattern along
with Post-Atrophic Hyperplasia (PAH).
Analysis of these PIN areas, which were contoured 16 times in MRI by the four
radiology observers, revealed that five contours were assessed as PI-RADs score
3, eight contours as PI-RADs score 4, and three contours as PI-RADS score 5.
Of the 23 corresponding histology areas to MRI, atrophy was present in seven
areas. Of these atrophic areas, 3 areas were found to be with post-atrophic
hyperplasia. One area had simple atrophy, and another was mixed between simple
and cystic atrophic subtypes. Two atrophic areas were admixed with a PIN, one
area displayed simple atrophy and another displayed simple and PAH. These
atrophic areas were contoured on MRI thirteen times by the four radiology
observers. Six contours were assessed as PI-RADS score 3, five contours were
assessed as PI-RADS score 4 and two contours with PI-RADS score 5.
BPH was found to be represented in five areas, which consisted of glandular and
stromal components. An epithelial component was represented in 60% or higher
in these nodules. On the corresponding MR images, the radiology observers
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contoured three of these five areas as PI-RADs score 3 and two areas as PI-RADS
score 4.
Normal prostate tissue was present in three areas on the digital histology images,
which corresponded to contoured regions on MRI as potential cancerous lesions.
One area was in the anterior fibromuscular stroma region, and the other two were
in the central zone structure.
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Figure 3.7. Histograms of the frequency of the PI-RADs score for the
individual non-cancerous lesions.

Sum of
Total
areas

PIN

Mixed
between
PIN &
atrophy

23

8

2

Atrophy

5

BPH

Normal
structures

5

3

Table 3.1. Summary of the total number corresponding digital histology image areas
to contoured MRI areas delineated by four Radiology observers.
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3.3
Analysis of PI-RADS Score Corresponding to
Histopathology Digital Images
(Figures 3.7 - 3.9) show the results of the analysis of each PI-RADS scored area
and their frequency of non-cancerous lesion as contoured by the four observers.
PI-RADS score 3 areas were contoured by the four observers fifteen times. The
corresponding histopathology images revealed that PIN, atrophy, BPH and a
normal structure were represented in 5, 6, 3 and 1 areas respectively.
A PI-RADS score 4 was evaluated and contoured by the four observers on MRI in
sixteen areas. The digital histopathology images, which corresponded to MRI
contoured areas revealed that PIN, Atrophy, BPH and normal structure were
represented in 8, 5, 2 and 1 areas respectively.
A PI-RADS score 5 was assessed six times on MRI by the four radiology
observers. The corresponding areas of these MRI contoured areas to
histopathology digital images demonstrated PIN, Atrophy, BPH and normal
structure presented in 3, 2, 0 and 1 respectively.
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Figure 3.8. Histogram characterizing the total frequency of each PI-RADS
score assessment provided by four radiology observers and their
corresponding non-cancerous lesions on digital histopathology images (n=19)
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Figure 3.9. Histograms of the frequency of total assessment of PI-RADS
score 3 for each of the four observers. (A) The graph shows the total number of
PI-RADS score 3 with the corresponding histology of non-cancerous structures on
digital image slides (n=19). (B) The graph shows the total number of PI-RADS
score 3 assessment by the four observers and their corresponding areas of noncancerous structures on digital image slides (n=19).
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Figure 3.10. Histograms of the frequency of total assessment of PI-RADS
score 4 for each of the four observers. (A) The graph shows the total number of
PI-RADS score 4 with the corresponding histology of non-cancerous structures on
digital image slides (n=19). (B) The graph shows the total number of PI-RADS
score 4 assessment by the four observers and the corresponding areas of noncancerous structures on digital image slides (n=19).
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Figure 3.11. Histograms of the frequency of total assessment of PI-RADS
score 5 for each of the four observers. (A) The graph shows the total number of
PI-RADS score 5 with the corresponding histology of non-cancerous structures on
digital image slides (n=19). (B) The graph shows the total number of PI-RADS
score 5 assessment by the four observers and the corresponding areas of noncancerous structures on digital image slides (n=19).
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The assessment of the 19 mpMRI prostate surgery cases illustrated that 23 areas
on histopathology digital slides corresponded with non-cancerous lesions. These
areas were assessed by the four radiology observers as a potential PCa on the
corresponding areas in the MRI images. Each of the 23 histopathology areas was
individually examined, verified and contoured in the MRI images by at least one
or more observers. These areas were contoured a total of 37 times by the
observers. Multiple areas were contoured by more than a single radiology
observer. (Table 3.2) displays the total number of times that the radiology
observers contoured areas, which were found to be non-cancerous when the
corresponding areas were examined in the histopathology slides.
Examination of the MRI images, which corresponded to the 23 digital
histopathology images showed that 16 areas were contoured only by a single
observer. Two areas were contoured twice by 2 different observers. Three areas
were contoured three times by 3 individual radiology observers. The each of last
two remaining areas were contoured by each of the four radiology observers
individually. The 2 areas contoured by 4 observers were PIN and Atrophy
(simple/cystic). The 3 areas contoured by 3 observers were a PIN. The 2 areas
contoured by 2 observers was atrophy (PAH). The remaining 16 areas contoured
by a single observer as follow; 3 areas were normal structure, 4 areas were a PIN,
2 areas were mixed between atrophy and PIN, 2 areas were atrophy and 5 areas
were BPH.
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Table 3.2. The total non-cancerous area on histology and their contoured
frequency by radiology observers on the corresponding mpMRI image. The
first column shows the total number of non-cancerous areas on histopathology
digital images, which were contoured on the MRI images. The other columns
show the total number of times the observers contoured the non-cancerous areas
on the MRI images by the number of involved radiology observers.
Total involved
areas on
digital
histopathology

Areas
contoured by
a single
observer on
mpMRI

Areas
contoured by
two
observers on
mpMRI

Areas
contoured by
three
observers on
mpMRI

Areas
contoured by
four
observers on
mpMRI

23

16

2

3

2
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Chapter 4

4

Discussion and Conclusion

Prostate Cancer is one of the most common cancers in men, yet screening tools
including PSA, DRE, and Transrectal Ultrasound-guided (TRUS) biopsy do not
provide the desired high accuracy for PCa early detection and management.
The accuracy of TRUS biopsy is still debated especially in cancer-negative
biopsies and the medium rise in PSA levels between 4-10 ng/ml [74]. TRUS
biopsy is seen to have a higher chance of discovering large cancer volume rather
than higher cancer grades. However, the chance of detecting prostate tumours is
lower in the early stages of cancer with a smaller volume. TRUS is still the
primary imaging guiding tool for detecting PCa through biopsy [94]. Other
studies submitted that only 28% of the prostatectomy specimen is associated with
the original cancer grade in biopsy specimens [93]. Higher Gleason grades during
biopsy were associated with poorly differentiated cancer after processing the
whole prostate specimen following a prostatectomy [93].
The emerging MRI scanning protocol for imaging the prostate gland has a
significant role; that is to provide a high-resolution prostate image, assist in
detection, diagnosis, and staging the prostate tumour. Multi-parametric MRI
(mpMRI) is not only involved in prostate cancer diagnosis but also in
management. A controversial disagreement is present between Radiologists and
Urologists on when mpMRI images should be prescribed [96]. Radiologists claim
that biopsies will result in prostate haemorrhage that could take several months to
resolve. Haemorrhage and bleeding parenchymal spots will alter prostate MRI
assessments, which is a challenging for accurate tumour localization. The mpMRI
could provide a highly, detailed anatomy of the prostate gland and surrounding
structures assisting in determining the location for lesion sampling. The current
guideline sets the MRI after a prostate biopsy associated with no tumour
detection. On the other hand, the financial and logistic problems accompanying
MRI are still one of the leading hindrances. Many imaging centers do not have the
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capacity or equipment to compensate for a high number of patients for regular
prostate screening MRI scans.
The sensitivity and specificity of cancer detection with mpMRI reaches 80% for
clinically significant cancer volume more than 0.5 cc in the anterior area of the
prostate. This percentage increases to 90% for cancer located in the posterior
gland [135]. The MRI sensitivity for detecting small prostate cancer volume (less
than 0.5cc) is low; however, about 98% of these undetectable cancer lesions on
MRI are low-grade prostate cancer [126, 136]. Prostate tumour volume less than
0.5 cc is unlikely to be associated with aggressive disease, especially if it is a pure
Gleason grade 3 and Gleason score 6 [137]. The initial aim for prostate MRI is to
detect the most significant tumour, not every single lesion compared to breast
MRI’s [126]. Relative to TRUS, mpMRI is more accurate in detecting gland
volume with adjacent anatomical structures and extra-prostatic extension (EPE)
[93].
The PI-RADS score system is a developing tool for assessing and differentiating
the presence of prostate tumours and non-cancerous lesions in prostate gland MRI
images. The probability of prostate tumour evidence is directly proportioned with
the higher overall PI-RADS score. The PI-RADS score may also be used as a tool
for assessing tumour aggressiveness and extra-prostatic extension. The overall PIRADS score 1 and 2 reveal that the probability of cancer is very unlikely. It is
associated with the high probability of benign lesions being present. The overall
PI-RADS score 4 and 5 are reflect the high probability of existing cancer. PIRADS score 3 acts as an intermediate zone between 2 possibilities [123]. Our data
demonstrates that PI-RADS score 3 was specified in 15 radiology contours on
mpMRI images. PI-RADS score 4 was labeled in 16 radiology contours compared
to 6 contours labeled with PI-RADS score 5. None of these contours were
correlated to a prostate tumour area on histopathological images. In fact, these
contours were correlated to non-cancerous abnormalities that have been described
in the Results section above.
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Our study provides preliminary results on the relationship between non-cancerous
abnormalities that could mimic cancer-like signals on prostate gland mpMRI and
digital histopathology images. In our study, the non-rigid Target Registration
Error (TRE) of MRI to histopathology digital images was 1.1 ± 0.7 mm [129]. In
other studies, these relationships have not been examined with the same accuracy
for the correlation between digital histology images and mpMRI images as
completed in our study.
The analysis of our study should be interpreted within the context of the study
population. The analysis of 19 prostatectomy specimens shows that BPH, HGPIN,
Atrophy and normal structure (CZ, AFMS) were presented in 37 radiology
contours as potential lesions of PCa. These non-cancerous lesions had displayed
cancer like signals on mpMRI along with an assessment of PI-RADS score
ranging from 3 to 5 by our 4 radiology observers.
BPH was present in 5 histopathology areas with PI-RADS score 3 and 4. PIRADS score 3 was assigned to 3 BPH areas out of 5. The remaining 2 areas were
assessed as PI-RADS score 4. The BPH tissue in these 5 areas was composed of
the glandular and stromal components. The glandular component was the major
element of these nodules with minimal stromal tissue within BPH nodules. Visual
qualitative assessment of these nodules revealed that glandular component
composed of at least 70% to 80% of BPH areas with minimal stromal tissue inbetween.
PIN is widely accepted as a known PCa precursor due to the similarity in genetic
and cell morphology except in acini basement membrane invasion, which is
associated with PCa. PIN includes 4 main morphological patterns: papillary,
tufting, flat and cribriform. However, no known clinical significant impact exists
between these different types of patterns. Their recognition arises from the
diagnostic efficacy.
Our data revealed that PIN was represented in 10 histopathological areas with no
dominant or consistent pattern. Each of these patterns (tufting, papillary and flat)
was represented in 2 areas. The cribriform pattern was represented in 1 area, and
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mixed pattern between flat and tufting was represented in 2 areas. Another mixed
pattern between papillary and cribriform type was present in 1 area.
PIN features include hypercellularity, accompanied by basophilic appearance
similar to prostate adenocarcinoma. Although the PIN glands are usually
relatively larger in size compared to PCa glands, the basal cell layer is still abrupt,
discontinued, or in countless cases are not visible especially with H&E stain. This
is a characteristic feature for PCa as well. The PIN nuclear complex features
include nuclear enlargement, crowding, and hyperchromasia are another typical
findings in PCa cells. With PIN involvement, it is difficult to draw a clear
separation of atypical or normal cells from nuclear presentation based on H&E
stain only. Most of the time, additional immunohistochemical staining is required
for further differentiation especially in prostate gland biopsy tissue. In addition to
the loss of basal cell layer, hypercellularity and hyperchromasia are responsible
for the decreased water permeability and restriction in fluid transfer between cells
and between intracellular and extracellular space. This results in low water
content in the zonal tissue similar to cancer features. The diminished water tissue
content responsible for low signal intensity in T2W sequence and the hypointense
signal on ADC map are the same findings in existing PCa.
The similarity in histologic features between PIN and PCa cells such as cellular,
nuclear and glandular features are accountable for the major portion in signal
similarity on mpMRI.
Atrophy was found in 7 histopathological areas. The Post-Atrophic hyperplasia
(PAH) represented the majority of atrophic glandular changes. PAH was present
in 4 areas, 3 areas with PAH, and one area mixed with a flat pattern of PIN.
Another area with cystic atrophy was present with PIN features mixed with
patterns between flat and tufting. Simple atrophy was present in 1 area. A mix
between PAH and simple atrophic gland was present in 1 area. In general, the
Atrophic glands are accompanied by inflammatory cells. Our data illustrates no
large significant inflammatory cell patches in-between atrophic glands correlated
to cancer like signal on mpMRI. The basal cell layer is diminished in glands with
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atrophic features. Occasionally a complete lack of basal cells are seen. This
feature presents itself in adenocarcinoma of the prostate. In the case of PAH, the
glands appear basophilic at low power. The multiple, small acini packing is
responsible for the hyperplastic appearance with an increase in cellularity
compared to normal glandular tissue. The nucleolar may also display mild to
moderate enlargement. This is also a feature of PCa and could raise confusion in
distinguishing between PAH and prostate adenocarcinoma in the pathology
setting. The similarities between PCa and atrophy are hypercellularity, mild to
moderate nuclear, nucleolar enlargement, and attenuated to complete lack of basal
cell layer could be responsible for a similar signal on mpMRI.
The remaining 3 histopathological areas were represented by a normal or nonpathological structure. The normal central zone glandular component was
represented in 2 areas. The CZ glands are more complex compared to PZ glands
with significant papillary foldings and piled up nuclei. These features increase the
possibility for CZ glands to be diagnosed as a PIN. Anterior-fibromuscular stroma
was present in the last remaining area.
Our data showed that the 2 histopathology areas that were contoured by 4
observers were atrophy and PIN. The atrophy area contained a mix of cystic and
simple atrophy sub-type. The PIN area demonstrated a papillary pattern.
Our study required approximately 3 extra days of processing compared to regular
histology processing time. This processing time is for fiducial applications, apex,
base, and mid-gland sectioning and photographing formalin sections. A set of ex
vivo MRI images were aquired after fiducial applications. This results in the delay
of the pathological assessment by 4-5 days.
One of the technical challenges of the study is the registration between
histopathology digital images and in vivo mpMRI images for the apex first cut.
This is performed through an interactive digital technique using T2W, T1W and
ex vivo MRI images of the prostate gland specimens after prostatectomy.
The clinical pathology processing protocol allows only prostate mid-gland for
whole-mount slicing. The whole-mount blocks ranged between 3 to 5 blocks per

89

prostate specimen depending on the prostate gland shape and volume. This
procedure excluded the assessment of the apex and base of the prostate in
correlation with mpMRI due to lack of registration between digital histopathology
images of apex and base and mpMRI images.
The results included multiple observers involved in the radiology contours, which
displayed a significant inter-observer variability. Sixteen areas were contoured
with a single observer, two areas were contoured with 2 observers, three areas
were contoured with 3 observers and 2 areas contoured with 4 observers. Also,
through case examinations, some areas with adenocarcinoma on the digital
histopathology images were not associated with any radiology contours or
recognition on mpMRI images by the 4 radiology observers. Further
investigations are required to explore the cause of this finding as this was beyond
the scope of this study.
The assessment of mpMRI by 4 radiology observers was achieved using PIRADS score V1. The PI-RADS score V1 went through some amendments to
increase clarity and reduce inter-observer variability. PI-RADS version 2 (V2)
was published in 2015 as a result of these acquired changes [138]. The PI-RADS
V2 has introduced the concepts of domain sequence in assessing prostate zonal
anatomy [138]. DWI was assigned as a domain sequence in PZ assessment since
T2W images were accompanied by the lack of specificity with low signal
intensity [138]. The T2W low signal intensity may have occurred from noncancerous lesions such as inflammation (acute or chronic) or haemorrhage. The
DCE sequence comes secondary to DWI in evaluating PZ. The DCE went from a
5 points score to a positive or negative assessment, which reflects the possibility
of the presence or absence of cancer respectively [138]. Score 3 on DWI should
be upgraded to score 4 if corresponding DCE area shows a positive signal.
Additionally, lesion size and shape were introduced as factors in the assessment.
The cut-off size is ≥1.5 cm upgraded score 4 to score 5. DWI scoring categories
went through major modification in V2 in contrast to V1. The primary sequence
in evaluating TZ is a T2W image. The BPH in TZ accompanied by increased
cellularity and reduced diffusion raising the suspicion for PCa presence. The cut-
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off size lesion is ≥1.5 cm between score 4 and 5, which was not considered an
influence on V1. It is still early to evaluate how significant PI-RADS
classification amendments will impact the clinical diagnostic performance.
Further changes may be implemented in the future. Some studies concluded that
the modification included in V2 has increased the sensitivity in assessing TZ
compared to V1; however, the sensitivity of PZ assessment is slightly better with
the V1 scoring system [139]. Our radiology observers’ assessment was performed
according to PI-RADS V1 prior to PI-RADS V2 publication. From the
comparison between the two versions, our data could be slightly impacted by
increasing the sensitivity in TZ evaluation. Our data demonstrated 5 areas that
were contoured as potential cancerous lesions in TZ on mpMRI with BPH finding
on corresponding histopathology images. Three of these 5 areas were classified as
score 3 and the remaining 2 were classified as PI-RADS score 4. Training and
experience will play an essential role in interpreting prostate mpMRI images since
there was a significant inter-observer variability between radiology observers
associated with variable years of experience.
Overall, our study demonstrated the relationship between false positive cancer
like signals on prostate gland mpMRI and their corresponding pathological noncancerous abnormalities. Our data showed 3 major categories of non-cancerous
lesions (Atrophy, PIN, and BPH) associated with the false positive mpMRI
signals. The examination of these 3 major categories revealed no consistent
pattern or subtypes responsible for this signal similarity with cancer on mpMRI
images. Surprisingly, our data displayed no inflammation, whether, acute or
chronic, which were associated with false positive cancer signal on mpMRI.
The use of our current research method with a larger sample size may provide a
vital tool in better understanding and answering the previous research questions
regarding developing a map of non-cancerous pathology lesions and their signals
on mpMRI.
More research should be directed towards the relationship between multiple noncancerous pathology lesions present in the same zone and their signals on
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mpMRI. The examination of areas that contain multiple mixed types of noncancerous abnormalities could provide essential data when correlated to mpMRI
signals. Together with the above recommendations, the stromal glandular ratio
should be examined in correlation to mpMRI signals. The attenuated, disruptive
or even complete absence of basal cell layer is an existing co-finding between
prostate adenocarcinoma and other non-cancerous lesions such as PIN and
atrophy. Further quantitative and qualitative assessment of the basal cell layer and
its relationship to water permeability and fluid restriction may provide valuable
data on basal cell presence and its impact on mpMR images. This relationship
may have a significant input in understanding the similarity between
adenocarcinoma and other non-cancerous lesions on mpMR images. This data, in
collaboration with further research, can assist in improving the differentiation
between cancerous and non-cancerous lesions, reducing the rate of false positive
diagnosis of PCa on MRI.
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